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ABSTRACT
UTILIZING FLUORESCENCE MICROSCOPY TO CHARACTERIZE THE SUBCELLULAR
DISTRIBUTION OF THE NOVEL PROTEIN ACHERON
September 2021

VARUN SHEEL, B.S., UNIVERSITY OF MASSACHUSETTS AMHERST

B.S., UNIVERSITY OF MASSACHUSETTS AMHERST

M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Lawrence M. Schwartz

All cells carry the genetic machinery required to commit cell suicide; a process known as
programmed cell death (PCD). While the ability to initiate PCD serves a number of useful
purposes during development and homeostasis, misregulation of PCD is the underlying basis of
most human diseases, including cancer, autoimmunity disorders and neurodegeneration. Using
the tobacco hawkmoth Manduca sexta as a model organism, the Schwartz lab at UMass has
demonstrated that PCD requires de novo gene expression and has cloned many death-associated
genes. One of these genes encodes a novel protein that was named Acheron after one of the
rivers of the Underworld in Greek mythology.
1

Acheron (also known as Lupus Antigen Related Protein 6; Larp6) is an RNA binding
protein that mediates a number of cellular processes, including cell survival, angiogenesis,
migration, and differentiation. The molecular mechanisms that mediate Acheron’s diverse roles
are poorly understood, but several lines of evidence suggest that it is mediated in part by proteinprotein interactions and motifs that target it to different cellular compartments. In this thesis, I
employed immunofluorescence and confocal microscopy to conduct two studies employing
mammalian cells. The first study was to determine the subcellular localization for Acheron in
normal cells and cells treated with growth factors. I found that Acheron predominantly coincides
with the microtubule cytoskeleton.
In our second study, I tested the hypothesis that Acheron’s binding partners BAD,
Human Homolog of Ariadne-1 (HHARI) and Calcium/Calmodulin-dependent Serine Protein
Kinase (CASK) colocalize with Acheron. As part of this analysis, I sought to determine if
Acheron could facilitate the translocation of CASK to the nucleus. I found that Acheron localizes
predominantly to microtubules, with some expression in the cytoplasm and nucleus. When
Acheron and its partners are co-labeled in cycling mouse C2C12 myoblasts or human U2-OS
osteosarcoma cells, Acheron did not colocalize with BAD, HHARI or CASK on
microtubules. However, I found tat when Acheron is driven into the nucleus with high levels of
growth factors, CASK also appeared to translocate to both the nucleus and to microtubules, where
it colocalized with Acheron.

v

The data acquired through these studies should provide not only insights into the
subcellular distribution of Acheron and its potential binding partners but may also help elucidate
its roles in programmed cell death, differentiation, and pathogenesis in mammalian models.
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CHAPTER I

INTRODUCTION
Programmed Cell Death:
All cells carry the genetic machinery required to commit cell suicide; a process known as
programmed cell death (PCD). Successful initiation of PCD serves a number of essential roles
during development and homeostasis. However, misregulation of PCD serves as the basis for
human pathogenesis in cancer, autoimmune disease and neurodegeneration.
Karl Vogt documented the first ever observation of cell death in 1842. In his studies,
Vogt characterized cell death of the notochord and adjacent cartilage in metamorphic toads (Vogt,
1842). This marked the beginning of a golden age in science, riddled with discoveries in
development such as Dreisch’s 1895 work examining urchin embryo development and Spemann
and Mangold’s documentation of “organizers” in the African clawed toad Xenopus laevis.
However, Vogt’s findings were never shown in a “spotlight” until almost 100 years later. In 1951,
Alfred Glucksman returned cell death as a focus of developmental research in his review “Cell
Death in Normal Vertebrate Ontogeny”. In this review, Glucksman documents his observations
of notochord core disappearance in development. These findings inspired many to pursue
research in the field of PCD, including Richard Lockshin and Carroll Williams.
Between 1964 and 1965, Lockshin and Williams published a series of five articles
entitled “Programmed Cell Death” in the Journal of Insect Physiology. These articles examined
and discussed the neuronal, cellular and hormonal pathways controlling intersegmental muscle
(ISM) cell death in the American silk moth Antheraea polyphemus following eclosion at the end
of metamorphosis. These articles not only mark the first uses of the now standardized term
“Programmed Cell Death”, but they also inspired a new wave of research into a field that had not
attracted much attention. In 2002, the Nobel prize in Physiology or Medicine was awarded to
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Sydney Brenner, Robert H. Horvitz and John E. Sulston for their discoveries regarding the
genetic regulation of organogenesis and programmed cell death in the nematode Caenorhabditis
elegans. These discoveries provided insight into the critical roles PCD plays in development and
homeostasis. It is estimated that defects in the regulation of PCD serve as the basis of over 70%
of human disease (Reed, 2002). Inappropriate activation of PCD serves as the basis of a number
of neurological diseases such as Parkinson’s Disease, in which groups of striatal dopaminergic
neurons die (Hartman et al., 2000). Conversely, the failure to initiate PCD to remove harmful
mitotically-component cells through PCD provides the basis of all autoimmune diseases and most
cancers (Renehan et al., 2001).
The best understood mechanism of cell death is apoptosis. This process is typically
mediated by a family of cysteine proteases known as caspases (Miura et al., 1993). Apoptosis can
be triggered through a wide array of external and internal stimuli, including but not limited to,
hormone exposure/loss, DNA damage, loss of contact with other cells, and pH changes (Norburry
et al., 2001). In short, exposure to these death inducing stimuli results in a cascade effect in which
zymogens (effector caspase zymogens) are activated via interchain cleavage mediated by initiator
caspases. This in turn triggers cleavage and activation of executioner pro-caspases. Executioner
caspases then cleave vital proteins in the cell, thereby leading to death during apoptosis (Elmore,
2007). A more thorough inspection reveals two main pathways for triggering apoptosis in
response to death inducing stimuli.
The first is the extrinsic pathway, which is initiated by the ligation of pro-death signaling
peptides to members of the tumor necrosis factor (TNF) family of death receptors at the cell
membrane (Micheau et al., 2003). Examples of this include ligands such as Fas-ligand (FasL),
TNF related apoptosis inducing ligand (TRAIL) and Tumor Necrosis Factor Alpha (TNFα),
which bind to receptors Fas, DR4/5 and TNFR1 respectively (Arai et al., 2014; Wiley et al.,
1995; Cabal-Hierro et al., 2012) . The binding of pro-death signaling ligands with TNF family
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pro-death receptors results in trimerization and subsequent death domain mediated recruitment of
death domain/adaptors such as Fas-associated protein with death domain (FADD) or Tumor
necrosis factor receptor type 1-associated death domain protein (TRADD). Complexation of these
molecules results in formation of the death-inducing signaling complex (DISC) (Scaffidi et al.,
1999). Formation of DISC’s allows enlistment and activation of procaspase-8 via death effector
domains (Irmler et al., 1997). Procaspase-8 is an initiator caspase that can cleave and activate
executioner pro-caspases such as caspase-3, -6 and -7, thereby triggering the execution phase of
PCD (Elmore, 2007). Activated executioner caspases then cause the morphological and
biochemical alterations associated with apoptosis (Slee et al., 2001). This includes chromatin
margination, DNA fragmentation, nuclear collapse and cleavage of essential substrates such as
PARP (poly (ADP-ribose) polymerase) (caspase-3/7) and lamin A/C (caspase-6) (Wajant et al.,
2002; Green and Llambi, 2015).
The second key pathway for initiating apoptosis is through the intrinsic (mitochondrial)
pathway. This pathway is the primary one that mediates apoptosis in vertebrates and can be
initiated by many of the same external and internal stimuli described above (Bratton et al., 2001,
Norburry et al., 2001). In this pathway, PCD is heavily influenced by mitochondrial stress
(oxidative stress)/mitochondrial outer membrane permeabilization (MOMP) and members of the
Bcl-2 (B-Cell Lymphoma 2) family of mitochondrial membrane proteins (Tait and Green, 2010).
Bcl-2 proteins can be divided into three subfamilies. The first subfamily are pro-apoptotic
effector proteins such as Bcl-2 associated X protein (Bax) and Bcl-2 homologous antagonist killer
(Bak). These proteins are both necessary and sufficient to cause MOMP (Moldoveanu et al.,
2020). The second subfamily includes anti-apoptotic regulatory proteins such as Bcl-2, B-cell
lymphoma-extra-large (Bcl-xL) or Mcl1 (Tsujimoto, 1998). These proteins prevent MOMP and
subsequent cell death. The third and final subfamily are BH3-only proteins. These proteins
include but are not limited to; BH3 interacting-domain death agonist (Bid), Bcl-2-like protein 11
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(Bim), Bcl-2 associated agonist of cell death (Bad), Phorbol-12-myristate-13-acetate-induced
protein 1 (Noxa), p53 upregulated modulator of apoptosis (PUMA) and Bcl-2 interacting protein
3 (Hutt, 2015). BH3-only proteins enable intrinsic pathway by either inactivating antiapoptotic
Bcl-2 proteins or by activating proapoptotic Bcl-2 proteins (Delbridge et al., 2016).
In the intrinsic cell death pathway, proapoptotic Bcl-2 proteins directly lead to MOMP
(Eskes et al., 2000). Following activation, proteins such as Bak or Bax oligomerize in the
mitochondrial outer membrane thereby forming pores in the mitochondrial outer membrane (Peng
et al., 2009). This leads to MOMP and results in the release of mitochondrial intermembrane
space proteins, including cytochrome c, Smac/Diablo and Omi (Goldstein et al., 2000; MunozPinedo et al., 2006). Once in the cytosol, cytochrome c binds to Apoptotic Protease-Activating
Factor 1 (APAF1) (Zou et al., 1997). Binding of cytochrome c to APAF1 triggers hydrolysis of
the APAF1 cofactor dATP to dADP (Kim et al., 2005), which in turn allows oligomerization of
multiple APAF-1-dATP-cytochrome-c subunits, thereby forming an active apoptosome (Yu et al.,
2005). Following apoptosome formation, the intrinsic cell death pathway utilizes caspase
enzymes similar to the extrinsic cell death pathway.
Caspase-9 binds to exposed caspase recognition domains (CARDS) at the center of the
apoptosome (Yuan et al., 2010). Proximity of caspase-9 monomers results in a chain reaction and
a continuous cycle of caspase-9 recognition, binding, activation, processing and displacement
(Malladi et al., 2009). While in normal circumstances caspase-9 catalytic activity is inhibited by
X-linked inhibitors of apoptosis (XIAP), prior release of Smac and Omi during MOMP causes
them to bind to and inhibit XIAP (Tait and Green, 2010). XIAP induces direct ubiquitination and
degradation of caspases via the ubiquitin proteasome pathway (UPP) Eckelman et al., 2006).
Deactivation of XIAP results in increased availability of initiator caspase-9 as well as executioner
caspases-3 and -7 (Green and Llambi, 2015). As in the extrinsic pathway, initiator caspase-9 then
cleaves and activates executioner caspase-3 and -7 (Elmore, 2007). Executioner caspases then
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activate cytoplasmic endonuclease and cytoskeletal peptide proteases which can in turn degrade
essential nuclear proteins such as PARP (poly (ADP-ribose) Polymerase) (caspase-3/7) and lamin
A/C (caspase-6). (Slee et al., 2001; Wajant et al., 2002; Green and Llambi, 2015).

PCD of Manduca ISM:
In studies of the American silkmoth, Antheraea polyphemus, Lockshin and William
examined the loss of intersegmental muscles (ISM’s) at the end of metamorphosis (Lockshin and
William, 1965), a process initially described in 1935 by Kuwana et al., and expanded upon in
1956 by Finlayson. Adult moths utilize these ISM’s to ecclose from their pupal cuticle at the end
of pupal/adult development. These muscles then undergo autophagic death over the next 30 hours
(Finlayson, 1956; Beaulaton & Lockshin, 1977; Schwartz et al., 1993). While this phenomenon of
ISM loss in moths is well characterized, the mechanisms underlying this behavior remain
uncertain.
Using the Tobacco Hawkmoth, Manduca sexta as a model organism, the Schwartz lab at
UMass Amherst examined the molecular mechanisms that mediate this phenomenon. In 1983
Schwartz and Truman discovered that ISM atrophy begins on day 15 of pupal development
(Schwartz and Truman, 1983). At this point the ISM’s undergo hormonally-regulated atrophy,
controlled by a class of steroid hormones called ecdysteroids, during which they lose 40% of their
muscle mass and up to 20% of their volume (Schwartz and Truman, 1983). The ecdysteroid
hormone in question was identified to be 20-hydroxyecdysone (20E), the insect molting hormone.
This process is accompanied by a marked increase in polyubiquitin mRNA expression and
proteolysis (Schwartz et al., 1990a; Tsuji et al., 2020).
Further decline of circulating levels of 20E on day 17 of pupal development, induces release of
the peptide hormone Eclosion Hormone (EH) (Schwartz and Truman; 1982). EH acts as the
proximal trigger for death. Following the release of EH, PCD is marked by a rapid loss of muscle
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mass (~4% per hour following eclosion) (Schwartz and Truman 1983). Administration of
exogenous 20E on the day before eclosion inhibits ISM PCD (Schwartz and Truman, 1984).
In 1969 Lockshin further explored the phenomena of PCD by demonstrating ISM PCD in
Antheraea polyphemus could be blocked by inhibitors of both RNA and protein synthesis
(Lockshin and Williams, 1969). This served as the basis for suggesting that PCD in silkmoths
requires de novo gene expression. This was verified later by Schwartz et al., in 1990a. By
utilizing the Manduca ISM model the Schwartz lab became the first researchers to clone deathassociated genes. These included some known molecules such as polyubiquitin, 20S and 26S
proteasome subunits and apolipophorin (Schwartz et al., 1990b; Sun et al., 1995; Jones et al.,
1995; Sun et al., 1997). However, others were novel proteins whose role in PCD was not yet
understood. This includes molecules such as small cytoplasmic leucine rich repeat protein
(SCLP), death associated LIM-only protein (DALP) and finally, Acheron (Hu et al., 1999;
Kuelzer et al., 1999; Valavanis et al., 2007).
Using a differential cloning strategy to identify genes that were induced or repressed
when the ISMs became committed to die, Valavanis et al (2007) cloned an induced sequence that
they named Acheron (Achn) after one of the rivers of death in Greek mythology. Northern blot
analysis of Acheron mRNA expression in Manduca ISMs demonstrated Acheron is dramatically
induced on day 18 of pupal development when the ISMs become committed to die (Valavanis et
al., 2007). Subsequent quantification via qPCR demonstrated that Acheron is induced ~1,000-fold
on day 18 (Sheel et al., 2020). Injecting day 17 of pupal development with 20E delayed both ISM
death and Acheron expression (Valavanis et al., 2007).

Acheron and PCD:
Acheron (LARP6) is a 55kDA, phylogenetically conserved member of the Lupus Antigen
(LA) family of RNA binding proteins. La-related proteins (LARPs) are RNA binding proteins
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comprising a well-conserved RNA recognition motif (RRM) and a functional, winged helix-turnhelix structured RNA binding, LA motif (LAM) (Stefanovic et al., 2014; Martino et al., 2015;
Bousquet-Antonelli et al., 2009). As well, Acheron contains a functional nuclear localization
signal (NLS), nuclear export signal (NES) and Suz-C (subcellular localization and mRNA
substrate recognition) domain (Valavanis et al., 2007; Stavraka et al., 2015).
Recent data by Dermit et al. demonstrates the importance of Acheron in ribosomal
protein coding mRNAs (RP-mRNAs) localization and translation. Acheron also binds to serinethreonine kinase receptor-associated protein (STRAP) via its SUZ-C domain to facilitate Acheron
localization and enrichment at actin-rich cell protrusions. Here Acheron colocalizes with RPmRNAs, which results in enhanced RP synthesis, upregulated ribosome biogenesis and increased
cell wide protein synthesis in migrating cells. In human breast carcinoma, Epithelial to
Mesenchymal Transition (EMT) results in upregulated Acheron expression and subsequent
enhanced protein synthesis (Dermit et al., 2020).
Acheron was originally cloned from the intersegmental muscles (ISMs) from the moth
Mnaduca sexta (references). Transcriptomins and qPCR have demonstrated that Acheron
expression increases 1000-fold on day 18 of pupal-adult development, when the ISMs become
committed to die (Sheel et al., 2020; Tsuji et al., 2020). In insects, on day 17 of pupal-adult
development, circulating levels of 20E decline below a threshold which triggers expression of
both eclosion hormone receptor and Acheron (Sheel et al., 2020). A further decline of 20E on day
18 triggers the release of eclosion hormone which acts on the muscles to drive production of
cGMP and the subsequent conversion of inactive protein kinase-G (PKG) into active PKG (PKG )
a

and Acheron phosphorylation.
In parallel studies, transcriptomics of Drosophila melanogaster throughout development,
demonstrated that Acheron mRNA is transiently induced ~600X prior to adult eclosion (Graveley
et al., 2010; Sheel et al., 2020). RNAi knockdown of Acheron expression in the muscles led to the
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precocious death of muscles, which normally die following adult eclosion (Gurbutt et al., 2013,
Sheel et al., 2020). Taken together, the data from Manduca and Drosophila suggests that Acheron
expression is correlated with muscle death during pupal development.
Mechanistic studies of Acheron function with Manduca ISM revealed that it interacts
with a pro-apoptotic BH3-only protein related to BAD (Sheel et al., 2020). Co-IP assays of
Acheron from day18 ISM extracts demonstrated Acheron binds with a novel 21kDa BAD-like
protein. Western blot revealed that while this protein was undetectable in early development,
expression increased on day 18 of pupal development, similar in timing to Acheron. Interestingly,
insects are reported to lack BH3-only proteins (Nicolson et al., 2015). However, RNA-seq
analysis of d18 Manduca ISM computationally identified a transcript expressed more than 10
RPKM which, when conceptually translated, was approximately 21kDa and had motifs with
homology similar to BH3 domains (Sheel et al., 2020). The identified molecule from this analysis
was a novel ortholog of Bnip3 that shares several domains of sequence similarity with BAD
(Sheel et al., 2020). This molecule was named BBH-1 (BAD/Bnip-3 Homology 1) by the
Schwartz Lab. While RNAi of Acheron in the Drosophila in the ptelinal muscles resulted in
precious muscle death and the failure of the pharate adults to eclose (Sheel et al., 2020). In
contrast BBH-1 RNAi blocked muscle death the flies closed normally (Sheel et al., 2020). This
suggests that BBH-1 directly regulates death of ecdysial muscles in Drosophila.
In mammalian models Co-IP analysis of Acheron binding partners in C2C12 myoblasts, a
presumptive satellite cell line derived from adult mouse muscle and a common cell line utilized
for the study of myogenesis, demonstrated that Acheron interacts with the pro-apoptotic BH3only protein, BAD (Sheel et al., 2020).
Co-IPs and yeast 2-hybrid screening revealed that Acheron binds to the ubiquitin ligase,
Human Homolog of Ariadne-1 (HHARI) (Wang et al., unpublished). HHARI is the closest
known homolog to the ubiquitin ligase Parkin (a known protein implicated in autosomal recessive
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parkinsonism) (Aguilera et al., 2000). Both proteins share similar RING (Really Interesting New
Gene) finger domains and bind to the same ubiquitin conjugases (UbcH7 and UBcH8) (Moynihan
et al., 1999). Taken together, these data suggest that HHARI may function similar to Parkin as a
ubiquitin ligase and be involved in regulating protein turnover (Marin and Ferrus, 2002).
Taken together, these findings support the hypothesis that Acheron functions as a
survival protein in part, due to its ability to bind to toxic BH3-only proteins (BAD in mammals
and BBH-1 in insect) (Sheel et al., 2020). Acheron binds to and sequesters the novel proapoptotic protein BBH-1 which then accumulates. Phosphorylated Acheron is then degraded,
presumably via the Ubiquitin Proteasome Pathway (UPP), thereby liberating BBH-1. BBH-1 then
is presumed to activate PCD through the intrinsic cell death pathway by inhibiting or bypassing
activity of anti-apoptotic Bcl-2 proteins, leading to MOMP (Sheel et al., 2020, Delbridge et al.,
2016).
Acheron and Myogenesis:
Acheron is a multifunctional protein that participates in a number of developmental
processes. Published data supports the hypothesis that Acheron is a vital regulatory molecule in
the differentiation of both ciliated cells and muscles in mammals (Wang et al., 2009; Glenn et al.,
2010; Manojlovic et al., 2017). In 2009 Wang et al., performed immunofluorescence (IF),
immunocytochemistry (ICC), Western blot and caspase assays in both C2C12 myoblasts and
zebrafish embryos to test the hypothesis that Acheron plays a vital role in myogenesis. The results
of these studies supported the hypothesis that Acheron expression is developmentally regulated in
C2C12 cells and Acheron plays an early and essential role in myogenesis and possibly the
regulation of muscle-restricted stem cell survival. The aforementioned experiments also support
the hypothesis that Acheron regulates the formation of fast and slow twitch fibers in vivo and
Acheron drives reserve cell death in differentiating cells and that this death occurs via apoptosis.
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One of the model systems that has been invaluable for analysing the expression and
function of Acheron is the mouse cell line C2C12. When deprived of growth factors these
myoblasts are capable of committing to one of three possible fates (Yaffe and Saxel, 1977). The
first path induces expression of the beta helix-loop-helix (bHLH) transcription factor MyoD
(myoblast determination protein) in a subset of cells. This cell cycle arrest and expression of the
bHLH protein myogenin and subsequent differentiation into multinucleated myotubes (Thayer et
al., 1989; Tapscott, 2005). The second possible pathway occurs when these cells express the
bHLH protein Myf5 (Myogenic factor 5). Expression of Myf5 causes myoblasts to exit the cell
cycle and arrest in G . These cells also upregulate the expression of the anti-apoptotic protein
0

Bcl-2 and become more apoptosis-resistant (Dominov et al., 1998, 2001; Yoshida et al., 1998).
Finally, a subset of cells fail to either form myotubes or to exit the cell cycle and instead default
to apoptosis (Dee et al., 2002).
Wang et al., demonstrated that Acheron expression was developmentally regulated in
C2C12 cells (Wang et al., 2009). Western blots of cycling and differentiated C2C12 cells revealed
MyoD, a nuclear phosphoprotein, drives myogenesis and facilitates the formation of
multinucleated myotubes (Tapscott et al., 1988; Wang et al., 2009). When deprived of growth
factors, MyoD expressing cells activate lineage markers, MyoA and MyoH. Once growth factors
are fully withdrawn or depleted, proliferating myoblasts receive differentiation cues from
neighboring cells.Acheron acts upstream of the muscle specific transcription factor MyoD to play
a critical role in myogenesis. When transfected with exogenous Acheron, cells formed larger
muscle fibers with a greater number of nuclei and displayed an almost complete loss of satellite
cells from the culture. Cells transfected with antisense Acheron demonstrated decreased levels of
myosin heavy chain (MHC), Myf5 and MyoD (Wang et al., 2009). Western blot analysis of cells
transfected with an N-terminally truncated form of Acheron (tAchn), which appears to function as
a dominant-negative regulator, revealed that these cells do not express MHC or MyoD, but do

10

express high amounts of Myf5, indicating cellular arrest in G (Wang et al., 2009). Taken together
0

these findings support the hypotheses that Acheron plays a vital role in myogenesis and cellular
differentiation and blockade of Acheron expression/function blocks myogenesis.
In order to gain insight into the molecular mechanisms driving Acheron’s role in
regulating myogenesis, Glenn et al., utilized immunofluorescence (IF) and migration assays with
C2C12 myoblasts and myotubes (Glenn et al., 2010). Cells were transfected with a plasmid coding
for the full-length sequence of Acheron (FL-Achn), tAchn or antisense Acheron (AS-Achn) and
subject to analysis for proteins vital to myogenesis such as MHC, and both A and B isoforms of
the laminin-specific integrin subunit, ɑ A and ɑ B. In cellular differentiation, cells undergoing
7

7

myogenesis require differentiation cues provided by neighboring cells and the extracellular
matrix. Interactions are regulated by transmembrane proteins called integrins (Boettiger et al.,
1995).
Ectopic expression of AS-Achn or tAchn blocked the expression of ɑ A e in cells
7

following transfer to differentiation medium (DM), while cells expressing ectopic Acheron
express elevated levels of these proteins of Acheron by the day 3 in DM (Glenn et al., 2010).
Conversely, basal levels of ɑ B protein and mRNA were found to be elevated in control and
7

Achn-expressing samples relative to ASAchn- and tAchn-expressing cells. Once transferred to
DM, ɑ B expression increased in both Achn-expressing and control samples, while the levels were
7

unchanged in ASAchn- and tAchn-expressing cells (Glenn et al., 2010). Analysis of Acheron
expression reveals an increase in myogenesis as well as down regulation of ITGB1, a key
molecule in regulating cellular adhesion (Glenn et al., 2010). Increased regulation of ɑ A and ɑ B
7

7

in the hours following transfer to engineered cells to DM indicates a migration phase that peaks
24 hours later (Glenn et al., 2010). This results in enhanced cell to matrix interactions and
increased adhesion to extracellular matrix components, a vital step in cellular proliferation and
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differentiation (Beacham et al., 2006). Taken together these findings propose potential
mechanisms that mediate Acheron-regulated myogenesis.
Similar to the Schwartz lab’s prior study in zebrafish, Hau et al. utilized morpholino
oligos to deplete Acheron mRNA from Xenopus embryos. Samples were then analyzed via RTPCR and whole mount in situ hybridization (WISH). The results of these studies revealed that
Acheron knockdown resulted in neural tube closure defects and a lack of cilia in the epidermis
due to downregulation of basal bodies at centrioles required for ciliary assembly. As well, these
authors reported that Acheron controls the expression of multicillate differentiation and DNA
synthesis-associated cell cycle protein (mcidas) in a Notch-independent manner. Mcidas activates
the transcription of centriole formation genes and could be used to partially restore multi-ciliated
cell differentiation in Acheron knockdown cells (Hau et al., 2020. These findings support the
hypothesis that Acheron is not only involved in myogenesis, but also ciliated cell differentiation
during development.

Acheron and Pathogenesis:
Misregulation of PCD is implicated in a wide range of diseases, including cancer,
muscular and neurodegenerative conditions, and AIDS (Nagata et al., 2017; Reed et al., 1999).
Triple negative basal-type breast cancer (TNBC) carries a poor patient prognosis, as it lacks the
three membrane growth factor receptors, estrogen receptor, progesterone receptor, and human
epidermal growth factor receptor 2 (ER, PR and HER2/neu respectively) that are traditional
targets for therapeutic intervention (William et al., 2010). Common cell lines used in research
models of cancer include TNBC cells such as MDA-MB-231 and Hs578T. Utilizing microarray
analysis and immunohistochemistry assays in breast cancer samples, Acheron expression was
found to be elevated in basal-type breast cancers when compared to controls (Shao et al., 2012).
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When engineered to express ectopic Acheron, MDA-MB-231 cells formed tumors that
were 5X larger than non-engineered MDA-MB-231 controls when transplanted into
immunodeficient SCID mice (Shao et al., 2012). Tumors expressing ectopic Acheron were also
more heavily vascularized. This presumably led to proliferation unimpeded by common
limitations of tumor growth such as nutrient deprivation and oxygen diffusion. Cells expressing
Acheron also demonstrated elevated invasiveness through Matrigel and elevated expression of the
protein matrix metalloproteinase 9 (MMP-9) and vascular endothelial growth factor (VEGF)
(Shao et al., 2012)
MMPs are synthesized as inactive zymogens. Following the proteolytic removal of the
pro-domain or residue modification, MMPs become active and degrade the extracellular matrix
(ECM) (Kessenbrock et al., 2010). Physiologically, this phenomenon is regulated via stimuli such
as inflammation and immune responses (Kessenbrock et al., 2010). Following activation, MMPs
break down the ECM surrounding proliferating tumors. This allows for cell migration and
subsequent inflammation, which initiates a positive feedback loop to secrete more MMPs. As
such, MMPs constitute one of the staple markers of aggressive tumors. When knocked down
(KD), MDA-MB-231 cells with MMP-9 KD demonstrated significantly lower degrees of
Matrigel invasion when compared to wild type cell lines. When transplanted into mice, tumors
with reduced MMP9 expression generated in tumors that were unable to metastasize to the lungs
of animals, while WT tumors could (Mehner et al., 2014).
MMP-9 differs from other MMPs in that it further enhances angiogenic activity by
triggering the release of activated vascular endothelial growth factor-A (VEGF-A) and vascular
endothelial growth factor receptor 2 (VEGFR-2) (Shibuya et al., 2011). VEGF-A binds to
VEGFR-2 and enhances endothelial cell proliferation. This in turn allows for enhanced
vascularization, tumor size and cell proliferation. Three markers in human cancer which
dramatically increase disease mortality (Wang et al., 2018).
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TNBC’s demonstrate increased invasiveness and angiogenic potential.
Immunohistochemical staining of human ductal carcinoma reveals Acheron expression is
elevated in aggressive tumors (Shao et al., 2012). Ectopic expression of Acheron in TNBCs
results in enhanced invasiveness and angiogenic potential. Taken together, these data support the
hypothesis that Acheron plays a critical role in TNBC pathogenesis.
Misregulation of Acheron may also contribute to liver pathogenesis. Fibrosis is a disease
characterized by elevated levels of type I collagen in various organs (Ghosh et al., 2002).
Acheron binds to the 5’ stem loop (5’SL) of type I collagen mRNAs in order to regulate their
subcellular localization and expression (Cai et al., 2010). This occurs via loop 3 of Acheron’s
RNA recognition motif (RRM), which simultaneously binds to the 5’ SL and sequesters the
complex to proteins such as the protein transport protein SEC61 translocon (Stefanovic et al.,
2014). Type I collagen synthesis then occurs upon phosphorylation of Acheron at the C-terminus.
There are 6 serine residues at the C-terminus, all of which become phosphorylated in a
hierarchical order to facilitate type I collagen synthesis. This begins with Protein kinase B
(Akt/PKB) -mediated phosphorylation of S451 and continues to include mammalian targets of
rapamycin complex 1 (mTORC1) mediated phosphorylation of S348 and S409. Misregulation of
phosphorylation at these sites or inhibition of Akt and mTORC1 results in inhibited and reduced
type I collagen synthesis, respectively (Zhang et al., 2016, 2017). Disruption of Acheron/collagen
mRNA binding via immunosuppressive drugs such as Tacrolimus (FK506) results in inhibition of
Acheron to 5’SL binding and dramatically reduced type I collagen synthesis (Manojlovic et al.,
2013).
Acheron is a dynamic protein that plays critical roles in PCD, myogenesis, cancer, and
hepatic fibrosis. While these two disease pathways have been documented, Acheron plays roles in
other pathologies that remain to be explored. Acheron is also associated with higher proinsulin
levels, one hallmark of the pathophysiology of type 2 diabetes (Strawbridge et al., 2011).
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Acheron’s capacity to play a role in multiple vital cellular processes can be further
understood by analyzing its ability to function as an RNA binding and signal transduction protein.
Calcium/Calmodulin-dependent serine protein kinase 3 (CASK) is a multidomain scaffolding
protein with the ability to participate in regulation of signaling by affecting; ion channels,
receptors and cell adhesion molecules in epithelial tissues, motor neurons and muscles
(Dimitratos et al., 1998). Yeast 2 hybrid screening with Acheron as the bait and a mouse
embryonic cDNA library as the prey revealed that CASK binds to the C-terminus of Acheron via
CASK’s CaM K II like domain (Weng et al., 2009). Binding of CASK and Acheron allows for
complexation with members of the Id (inhibitor of DNA binding/differentiation) family of helixloop-helix (HLH) transcriptional repressors and subsequent regulation of gene expression (Hsueh,
2006; Weng et al., 2009).
Acheron’s functional RRM, La Motif, and RBD enable Acheron to act as a key
regulatory molecule through RNA and protein-protein binding. In the case of type I collagen,
Acheron regulates type I collagen formation by binding to the 5’ stem-loop structure (SL) of type
I collagen mRNA. Binding of Acheron to the 5’SL enables collagen mRNA translation (Fritz et
al., 2011). Acheron forms a complex with structural proteins such as Myosin IIB and Vimentin,
which in turn binds to the 5’SL of type I collagen and sequester it to the ER membrane (Wang et
al., 2014; Cai et al., 2010; Manojlovic et al., 2012). Complexed Acheron then binds to the Cterminus of Serine-threonine kinase receptor-associated protein (STRAP) and RNA Helicase A
(RHA) and enables translation (Vukmirovic, 2013; Manojlovic et al., 2012).
Acheron is a dynamic molecule with key regulatory functions in PCD, myogenesis and
pathogenesis. Though the mechanisms mediating Acheron action are poorly understood, several
lines of evidence suggest that it is mediated by protein-protein interactions and its subcellular
localization motifs. In this dissertation I will employ immunofluorescence and confocal
microscopy to conduct two studies that will not only provide insights into the subcellular
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distribution of Acheron and its potential binding partners but may also help elucidate its roles in
programmed cell death, differentiation, and pathogenesis in mammalian models.
It is well established that understanding a protein’s subcellular localization can not only
elucidate the function of an individual molecule but can also help understand the organization of
the cell as a whole (Scott et al., 2005). Acheron is a dynamic protein with functional nuclear
localization and nuclear export signals with mechanistic roles in processes inside and outside of
the nucleus such as differentiation, programmed cell death and pathogenesis respectively
(Valavanis et al., 2007, Sheel et al., 2020). However, to date the exact subcellular localization of
Acheron is unknown. Given that Acheron interacts with BAD, a protein directly involved with
MOMP, in the first study I tested the hypothesis that Acheron localizes to mitochondria.
Evidence suggests Acheron’s role in PCD, myogenesis and pathogenesis is mediated by
protein-protein interactions. I will test the hypothesis that Acheron colocalizes with specific
binding partners, BAD, Human Homology of Ariadne-1 (HHARI) and Calcium/Calmodulindependent Serine Protein Kinase (CASK).
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CHAPTER II
DETERMINING THE LOCALIZATION OF ACHERON AND SPECIFIC BINDING
PARTNERS IN A MAMMALIAN SYSTEM
Introduction:
Acheron is a multifunctional protein that has numerous protein-protein interaction motifs that
presumably mediate many of its biological activities. However, some insights have been gained
regarding the subcellular mechanisms driving Acheron function have been revealed, much
remains unclear.

Binding
Partner
BAD/BBH1

CASK

HHARI

Vimentin

Evidence

Co-IP

Yeast-2-Hybrid,
Co-IP

Function

Localization

Agonist of cell
death.

Insect:Unknown
Mammal:Mitocho
ndria

Gene expression,
ion channel
regulation,
neuronal
differentiation.

Mammal:
Cytoplasm /
Nucleus

Yeast-2-Hybrid,
Co-IP

Ubiquitin E3
Ligase

Insect: Unknown

Co-IP, myosin
disruption

Structural protein

Intermediate
filaments

Reference

Sheel et al., 2020
Human protein
Atlas
Weng et al.,2009
Human Protein
Atlas

Mammal:
Unknown
Cai et al., 2010

Challa et al., 2011
Myosin IIB

CoIP, myosin
disruption

Smooth muscle
myosin
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Actin filaments,
mitochondria,
cytosol

Cai et al., 2010

STRAP

Pulldown Assay
Fractionated IP

snRNP assembly
catalyst

Cytosol

Vukmirovic et al.,
2013
Zhang et al., 2017
Human Protein
Atlas

Table 1a. Known Acheron Binding Partner Roles, Localization and Evidence:
A list of known Acheron binding partners with proven roles in PCD, myogenesis and
pathogenesis can be found detailed above. Accompanied with each molecule’s physiological role,
the localization of each molecule and the evidence available detailing its interaction with
Acheron, is also included in the table.
In order to investigate some of the molecular mechanisms associated with Acheron
function in mammalian systems, I utilized an anatomical approach to test three primary
hypotheses. The first study determined the subcellular localization for Acheron in mammalian
cells. Here I evaluated the binding of Acheron to mitochondria, actin filaments and microtubules,
respectively. Cycling mononucleated C2C12 mouse myoblasts,differentiated C2C12 myotubes and
U2-OS osteosarcoma cells were immuno-stained for Acheron to determine its cellular
localization. The second study tested the hypothesis that the homologs of Acheron’s binding
partners localize with Acheron in mammalian cells. For this study, Wild-type C2C12 myoblasts
and U2-OS osteosarcoma cells were stained for HHARI, BAD and CASK in relation to β-tubulin.
The third and final study tested the hypothesis that CASK translocates to the nucleus when
Acheron translocates to the nucleus in response to growth factor stimulation. To test this
hypothesis C2C12 cells expressing ectopic full-length GFP tagged Acheron and C2C12 cells
expressing ectopic full-length GFP tagged Acheron with deletions in their nuclear export signal (NES) were cultured on glass coverslips. Acheron was then driven into the nucleus by exposing
the cells to high levels of growth factors, where it was then trapped in -NES cells. Cells were then
stained for Acheron and CASK localization in relation to microtubules and analyzed for any
translocation.
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Materials and Methods
C2C12 Cell Culture:
C2C12 cells were grown at 37℃ in DMEM (Dulbecco’s Modified Eagle Medium) + 10%
FBS (Fetal Bovine Serum) + 1% penicillin/streptomycin in 10% CO2. To prepare a fresh growth
medium, 445 mL DMEM pH 7.2, 50 mL FBS and 5 mL Pen/Strep were combined via vacuum
filtration in a tissue culture hood at 25℃. Cells were then removed from storage in liquid
nitrogen and quickly thawed by swirling the tube in a water bath kept at 37℃. Once 70% thawed,
vials were removed from the water bath, sterilized with ethanol and transferred to 15mL conical
tubes with 5 mL of complete C2C12 DMEM medium and centrifuged at 500 x G for 5 minutes.
The supernatant was then discarded, and the pellets were resuspended in 10 mL of complete
C2C12 DMEM medium and plated on flat bottom, 10 cm dishes. Cells were then split every 48
hours (or when they reached ~70% confluency) by aspirating the existing medium and washing
the cells twice with PBS (phosphate buffered saline). The cells were then placed in 0.25% (w/v)
trypsin + 0.53mM EDTA (warmed to 37℃). Following cell separation from the bottom of the
dish, cells were once again transferred to a 15mL conical and centrifuged at 500 x G for 5
minutes. Supernatant was then discarded, and the pellets were resuspended in 10 mL of complete
C2C12 DMEM medium. Cells were then plated at a 1:10 ratio of cells vs fresh medium in a 10 cm
flat bottom dish.

C2C12 Differentiation:
To induce differentiation, C2C12 cells were grown to ~ 70% confluency and then
transferred to a low serum differentiation medium (DM): DMEM + 1% Pen/Strep + 2% horse
serum. Cells were grown in differentiation medium for 5 days at 10% CO 37℃, during which
2

time the medium was refreshed every 48 hours. Cells were monitored microscopically for
formation of myotubes indicating successful differentiation.
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Glass Coverslip Coating Removal and Poly-L-Lysine Treatment:
To increase cell-to-coverslip adhesion, glass coverslips (Fisher Scientific) were treated
with 21μM Poly-L-Lysine (Sigma Aldrich) for 15 minutes. Coverslips were removed from
packaging and placed on the shaker at 100rpm in 25mL 2M NaOH for 6 hours at 25℃.
Coverslips were then soaked in 20mL dH O and placed on the shaker at 150 rpm overnight at
2

25℃. Coverslips were rinsed under flowing dH O the next day and placed in the autoclave for
2

sterilization. Once sterile coverslips were cleaned with 70% ethanol and placed in the tissue
culture hood. Once in the tissue culture hood coverslips were covered with 10mL 21μM Poly-LLysine for 15 minutes at 25℃. Poly-L-Lysine solution was then aspirated, and coverslips were
left to air dry in the tissue culture hood with the filtration on overnight. Resulting coverslips were
considered sterile and fit for utilization in cell culture.

C2C12 + HA-Acheron -NES / +NES Mutant Acheron Translocation:
C2C12 cell lines expressing ectopic Acheron with an HA-tag were utilized for
experiments. Cycling C2C12 cells were transfected using a plasmid driving ectopic Acheron
expression by means of a CMV promoter. Constructs were then engineered via site directed
mutagenesis to create deletions in either the Nuclear Localization Signal, NLS (-NLS) or the
Nuclear Export Signal, NES (-NES) and introduced into cells (Shao et al., 2012). To determine
Acheron's role in the nucleus of the cell, we utilized mutant cells with faulty NESs and cultured
them at high growth serum to “drive” Acheron into the nucleus (Glenn and Schwartz,
unpublished). The cells were cultured in standard C2C12 growth medium (10% FBS in DMEM) at
37 °C and 10% CO on Poly-L-Lysine treated glass coverslips for 24 hours. Cells were then
2

placed in 3 mL DMEM + 1% Pen/Strep + 2% horse serum overnight, and then transferred back to
high growth serum medium (15% FBS) for 2 hours. Cells were then removed from the incubator
and medium was aspirated. Cells were then rinsed with 1X PBS and then fixed by adding 2 mL
4% paraformaldehyde pH 7.2 in 1X PBS at 4℃ and incubating at 25℃ for 10-15 minutes.
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Following fixation, paraformaldehyde was then removed and placed in hazardous waste.
Coverslips were covered with 1X PBS and dishes were sealed with parafilm so they could be
stored at 4℃ until they were ready for immunofluorescence staining.
Nocodazole Mediated Microtubule Depolymerization:
C2C12cells were treated with the antineoplastic agent, Nocodazole (Sigma Aldrich), in
order to induce microtubule depolymerization and disrupt microtubule associated protein (MAP)
interactions (Verstraelen et al., 2017). C2C12 cells were cultured on Poly-L-Lysine treated glass
coverslips in flat bottom 6 well dishes and cultured in GM at 37 °C and 10% CO on. Once the
2

cultures were at 70% confluence, the medium was aspirated and replaced with fresh growth
medium. Nocodazole was then added directly to each well to achieve a final concentration of
500nM and incubated for 1 hour at 37℃. Concentration was determined empirically as seen in
Figures 6a and b.
C2C12 and U2OS: Acheron, BAD, Ariadne, CASK, E7 Tubulin Colocalization
Immunofluorescence Staining:
C2C12 cells were cultured on poly-L-Lysine treated glass coverslips and grown in a flat
bottom 6 well dish in GM at 37 °C and 10% CO . Once cells achieved desired confluency, dishes
2

were removed from the incubator and surfaced sterilized with 70% ethanol. Dishes were then
moved into the tissue culture hood. Existing medium was aspirated from each well and the cells
washed with 1X PBS pH 7.2 until the red/pink coloring from the medium was removed. Cells
were then fixed by adding 2 mL 4% paraformaldehyde pH 7.2 in 1X PBS at 4℃ and incubating
at 25℃ for 10-15 minutes. Coverslips were covered with 1X PBS and dishes were sealed with
parafilm so they could be stored at 4℃ until they were ready for immunofluorescence staining.
To perform the immunofluorescence staining, samples were removed from the fridge and
washed once with fresh 1X PBS pH 7.2 at 25℃ for 5 minutes. Slides were then subject to a
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methanol permeabilization step to increase fluorescent signal and diminish autofluorescence.
100% methanol was placed at -20℃ overnight beforehand. Once slides were washed, coverslips
were placed on ice and covered with ice cold 100% methanol. Coverslips were immediately
placed at -20℃ for 8 minutes to prevent coverslips dehydration. After 8 minutes, existing
methanol was removed from each slide. Slides were then covered in fresh 1X PBS at 25℃ and
washed on the shaker at 300rpm for 5 minutes.
Following methanol permeabilization and washing, coverslips containing cells were then
incubated in immunofluorescence blocking solution. Blocking solution was made fresh during the
methanol permeabilization step by combining 5% goat serum (ThermoFisher Scientific) in 1X
PBS at 25℃ and mixing by inversion. Coverslips were then incubated in 1mL
immunofluorescence blocking solution overnight at 4℃ on the shaker at 200 rpm. During this
time dishes were also wrapped with parafilm to prevent slides from dehydrating.
The next day, blocking solution was removed from each coverslip and replaced with a
1mL fresh primary antibody dilution solution. Primary antibody dilution solution was made by
combining 2% BSA (Sigma Aldrich) (diluted in 1X PBS) in 1X PBS pH 7.2 at 25℃. Respective
primary antibodies were then added to their matching slides at the following dilutions and
incubated overnight at 4℃ on the shaker at 200 rpm. During this time dishes were once again
wrapped in parafilm to prevent coverslip dehydration.
1. Anti-Beta Tubulin; E7 (DSHB) - 1:350μL
2. Anti-Acheron: LARP6 (Schwartz Lab Purified) - 1:1000μL.
3. Anti-Ariadne: HHARI1 (Schwartz Lab Purified) - 1:5000μL.
4. Anti-BAD; BAD (Abcepta) - 1:500μL
5. Anti-BAD; BAD (LSBio) - 1:500μL
6. Anti-CASK C-Terminus; CASK (ABGENT) - 1:500μL
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Following incubation, dilution solution was removed from each well and slides were
washed 3X on the shaker at 350rpm in 1X PBS pH 7.2 at 25℃ for 20 minutes. Slides were then
covered with 1mL fresh 1X PBS pH 7.2 and fluorescent dyes were added to each respective slide
at the following dilutions. Slides were then placed in the dark and incubated in PBS/fluorescent
dye mixtures for 1.5 hours at 25℃.
1. DAPI (nuclear stain) - 1:300μL
2. Dylight 594- 1:500μL
3. Alexafluor 647 - 1:300μL
4. Alexafluor 488 - 1:500μL
5. Mitotracker CMXRos - 40μM
6. Rhodamine Phalloidin - 1:1000μL
Secondary antibody solutions were then removed from each slide and slides were once
again washed 3X on the shaker at 350rpm in 1X PBS pH 7.2 at 25℃ for 20 minutes. Coverslips
were then removed from wells and mounted face down onto labelled slides with 6.5μL
immunofluorescence mounting medium (4:1 glycerol in PBS). Edges of the slide were sealed
with clear nail polish to prevent coverslip dehydration and slides were allowed to dry overnight at
4℃ prior to imaging. Slides were then imaged on a Nikon A1R-SIMe resonant scanning confocal
super resolution microscope and processed in Fiji.
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Results
Acheron Localization in Mammalian Cells:
To determine the subcellular localization of Acheron in mammalian cells, cycling mouse
C2C12 myoblasts and differentiated C2C12 myotubes, as well as human U2-OS osteosarcoma cells
were processed for immunofluorescence staining of Acheron. Throughout these experiments,
areas of colocalization between Acheron (green) and other markers (actin, mitochondria, tubulin)
(red) can be inferred from the resulting yellow signal.
Co-IP of Acheron in C2C12 myoblasts demonstrated binding to e BH3-only protein BAD
(Sheel et al., 2020), a protein canonically found localized to mitochondria (Jiang et al., 2006). To
test the hypothesis that Acheron localizes to mitochondria with BAD in some circumstances,
mononucleated C2C12 myoblasts were stained for Acheron (green), nuclei (DAPI (4′, 6-diamidino2- phenylindole / DNA fluorescent dye) (blue) and mitochondria (Mitotracker CMXRos) (red)
and imaged at 60X on a Nikon Eclipse TE2000 inverted fluorescent microscope. While small
amounts of yellow signal can be seen in perinuclear areas of the cell, the majority of the Acheron
does not colocalize with the mitochondria (Figs 1a, b). Instead, Acheron expression appears to
predominantly localize to the nucleus and the cytoskeleton. The graph in Figure 1b displays
fluorescence intensity in arbitrary units (a.u) graphed against the diagonal length of the cell
(microns). Put more simply, this graph displays the brightness of each pixel relative to different
regions of the cell. DNA staining can be seen as the blue line, while Acheron and Mitotracker
intensities are represented by green and red lines respectively. The spike in DAPI (blue)
fluorescence can accurately be used as a marker for the nucleus of the cell. As a result, this figure
informs us where much of the Acheron is found within the cell (Figure 1a). Graphically, peaks of
Acheron (green) and Mitotracker (red) can be seen outside the nucleus (blue). This is presumably
our perinuclear colocalizing signal. Much of the remaining Acheron signal can be seen
overlapping with areas of DAPI fluorescence (blue). This demonstrates that much of the Acheron
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in this cell resides in the nucleus, while the rest is either found perinuclear or in the cytoplasm of
the cell (Figure 1b). This is supported by the staining seen in Figure 1c. Enhanced resolution of
Acheron staining shows the cytoplasmic, non-nuclear Acheron signal is not diffuse, but rather
appears to follow a specific cytoskeletal pattern (Figure 1c). The increased resolution of Acheron
staining in this Figure also provides us with enough resolution to see a distinct reticulated pattern
in our perinuclear Acheron signal. Concentrations of Acheron can be seen along the edge of the
nucleus. Acheron can also be seen following a distinct pattern towards the periphery of the
nuclear envelope but not immediately at the inner membrane and further out into the cell. This is
likely the perinuclear space and rough endoplasmic reticulum, respectively. Along with this,
small aggregates of Acheron can be seen towards the periphery of the cell, distinctly on
protrusions extending out of the cell and not the leading edge. This is likely localized to filopodia
and not lamellipodium (Figure 1c). This led us to believe that Acheron was localizing to
cytoskeletal structures of the cell.

Figure 1a.: Subcellular Localization of Acheron relative to Mitochondria in C2C12
Myoblasts
A z-projection of the nucleus (DAPI; blue; far left), mitochondria (Mitotracker; red;
second to the left), Acheron (anti-Acheron; green; second to the right) and composite (merge; far
right) channels of a single stained cycling mononucleated C2C12 myoblast, imaged at 60X. Some
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Acheron can be seen colocalizing with mitochondria at yellow regions of the image while the
majority can be seen in either the nucleus or cytoplasmic regions of the cell.

Figure 1b. Colocalization analysis of DAPI, Acheron and Mitochondria fluorescent signal
from figure 1a.
A graphical representation of fluorescence intensity for DAPI (blue), Mitochondria (red) and
Anti-Acheron (green) plotted relative to area on the cell. Acheron (green) fluorescence intensity
can be seen overlapping with mitotracker (red) at areas of perinuclear signal, however much more
of the Acheron signal can be observed overlapping with the DAPI (blue) signal at the nucleus of
the cell and at the cytoplasmic regions of the cell.
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Figure 1c. Acheron Staining Follows a Cytoskeletal Pattern in C2C12 Myoblasts.
A magnified view of Acheron (green) staining from Figure 1a. The cytoplasmic signal is
not diffuse, but rather, appears to follow a cytoskeletal pattern.

In order to test the hypothesis that Acheron binds to actin filaments, cycling C2C12
myoblasts were stained for Acheron (green), DNA (DAPI; blue) and actin (Rhodamine
Phalloidin; red) and imaged at 60X on a Nikon Eclipse TE2000 inverted fluorescent microscope
(Figure 2a). There are no areas of colocalization (yellow) in this figure, suggesting that Acheron
does not bind to actin filaments. However, Acheron can once again be seen aggregating towards
the edge of actin filaments (likely the filopodia). Acheron signal is also seen more diffuse in the
nucleus and around the nucleus, but pattern-like in the cytoplasm, indicating potentially different
molecular behaviors based on protein localization (Figure 2a). When presented graphically, the
data from Figure 2a allows one to draw the same conclusions. While Acheron (green) signal
follows a cytoskeletal expression pattern similar to rhodamine phalloidin (red) fluorescence, the
signals do not match, suggesting that Acheron (green) does not localize to Actin (red) filaments in
the body of the cell. However, much like Figure 1b, a spike of Acheron (green) expression can
also be seen to the periphery of Figure 2b as well. This is likely an enriched area of Acheron

27

localized to the filopodia of the cell. While this supports the data found by Dermit et al., an
absence of yellow fluorescence does not support the hypothesis that Acheron binds to actin
filaments (Figure 2b). Consequently, we turned our attention to another cytoskeletal structure,
microtubules.

Figure 2a: Subcellular Localization of Acheron Relative to Actin Filaments in C2C12
Myoblasts.
A z-projection of the nucleus (DAPI; blue; far left), actin filaments (Rhodamine
Phalloidin; red; second to the left), Acheron (anti-Acheron; green; second to the right) and
composite (merge; far right) channels of a single stained cycling mononucleated C2C12 myoblast,
imaged at 60X. There are no areas of apparent colocalization (denoted in yellow), suggesting that
Acheron does not bind to actin filaments. However, Acheron can still be seen in the nucleus and
in cytoplasmic areas following a cytoskeletal pattern.
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Figure 2b. Colocalization analysis of DAPI, Acheron and Rhodamine Phalloidin
Fluorescent Signal From Figure 2a.
A graphical representation of fluorescence intensity for DAPI (blue), Rhodamine Phalloidin
(red) and Anti-Acheron (green) plotted relative to area on the cell. Acheron (green) fluorescence
can be seen following a separate staining pattern from Rhodamine Phalloidin signal (red).

In order to test the hypothesis that Acheron binds to microtubules, we stained cycling

C2C12 myoblasts for Acheron (green), DNA (blue) and β-tubulin (red) (Figure 3a). There are two
tubulin monomers, β-tubulin and α-tubulin, that polymerize together to form microtubule
structures (Gunning et al., 2015). Overlapping the Acheron and β-tubulin signals revealed
substantial overlap (yellow), suggesting that a large majority of the Acheron protein (green) can
be seen colocalizing with β-tubulin (red) on microtubules (Figure 3a). As with prior Acheron
staining, green, fluorescent signal can be seen at cell protrusions, presumably in actin rich
filopodia. The exact degree of colocalization can be visualized graphically in Figure 3b. Similar
to Figure 1b, this graph also displays fluorescence intensity (a.u.) graphed against the diagonal
length of the cell (microns). In this Figure, DNA is represented as the blue line, while Acheron
and β-tubulin are represented by green and red lines respectively. While the DNA signal is
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localized to the nucleus of the cell as seen previously, the Acheron and β-tubulin signals can be
seen fluorescing at different intensities but in almost the exact same locations within the cell.
Acheron and β-tubulin signal intensifies in one area outside the nucleus as well (Figure 3b). This
is presumably the centrosome, a cellular structure that plays a critical role in microtubule
organization (Bornens and Azimzadeh, 2007). Towards the periphery of the cell, abnormal spikes
of Acheron (green) signal can be seen, graphically demonstrating the aggregates of Acheron
signal seen in cell protrusions. Taken together, these data support the hypothesis that Acheron
localizes to microtubules.
To test this hypothesis further, cycling C2C12 myoblasts were stained for Acheron (green),
DNA (blue) and β-tubulin (red), however these samples were imaged at 100X on a Nikon A1RSIMe resonant scanning confocal super resolution microscope rather than a Nikon Eclipse
TE2000 inverted fluorescent microscope (Figure 3c). Confocal microscopy differs from standard
inverted fluorescent microscopy as it utilizes a spatial pinhole to block out-of-focus light during
image acquisition. This dramatically increases optical resolution and contrast of microscopic
samples. As well, scanning confocal microscopes allows for the automated capture of multiple,
two dimensional images in a specified focal range. The resulting “z-slices” can be utilized for the
reconstruction of a three-dimensional structure. These tools become invaluable in co-localization
studies where two proteins are thought to be occupying the same space at the same time. Protein
localization analysis can be performed in z-slices up to 0.125 microns thick allowing for precise
co-localization analysis (Pawley, 2006; Jensen, 2004). For this image, a z-stack of approximately
0.625 microns thick (five 0.125-micron thick z-slices) was separated from the three-dimensional
reconstruction and processed. This section of the cell contains all the in-focus slices of
microtubules and Acheron, without contamination from the optical slices above or below. This
enhances resolution by removing optical “contamination” (Figure 3c). Once again, colocalization
between both proteins is represented by large regions of yellow fluorescence throughout the cell,
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aggregating again at the centrosome. As well as this, bright aggregates of green (Acheron)
fluorescence can be seen at the periphery of the cell similar to prior images. This further supports
our hypothesis that Acheron binds to microtubules. In this image, areas of distinct red
microtubules can also be seen at the edge of the cell. This is detail not provided to us by standard
inverted fluorescence microscopy.
This detail is made even more apparent when analyzed graphically as before. While
images provided by standard inverted fluorescence microscopy provides us with over hundreds of
data points of information to graphically analyze, images acquired via confocal super resolution
microscopy provide us with thousands, thereby increasing temporal resolution. Here Acheron
(green) signal can be seen precisely matching β-tubulin (red) signal. Acheron signal is also
independent of spikes in DAPI (blue) fluorescence (Figure 3d).

Figure 3a. Subcellular Localization of Acheron Relative to Microtubules in C2C12
Myoblasts.
A z-projection of nuclei (DAPI; blue; far left), microtubules (E7; red; second to the left),
Acheron (anti-Acheron; green; second to the right) and composite (merge; far right) channels of
stained cycling mononucleated C2C12 myoblasts, imaged at 60X. Small amounts of Acheron can
be seen localizing to the nucleus of the cell while a large portion can be seen colocalizing with
microtubules in yellow regions of the image, intensifying at the centrosome of the cell. This
indicates strong colocalization between Acheron and β-tubulin.
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Figure 3b. Colocalization analysis of DAPI, Acheron and β-tubulin Fluorescent Signal From
Figure 3a.
A graphical representation of fluorescence intensity for DAPI (blue), β-tubulin (red) and
Anti-Acheron (green) plotted relative to area on the cell. Acheron (green) fluorescence intensity
can be seen almost perfectly overlapping with β-tubulin (red) fluorescence indicating that both,
while being expressed at different intensities, can be found on identical areas of the cell.
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Figure 3c. Super Resolution Subcellular Localization of Acheron Relative to Microtubules
in C2C12 Myoblasts.
A confocal z-stack of the nucleus (DAPI; blue; far left), microtubules (E7; red; second to
the left), Acheron (anti-Acheron; green; second to the right) and composite (merge; far right)
channels of a single stained cycling mononucleated C2C12 myoblast, imaged at 100X. Some
Acheron can be seen in the nucleus while much of the Acheron in the cell can be seen colocalizing with
microtubules in yellow regions of the image with brighter pockets of yellow fluorescence at the centrosome
of the cell.
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Figure 3d. Colocalization analysis of DAPI, Acheron and β-tubulin Fluorescent Signal From
Figure 3c.
A graphical representation of fluorescence intensity for DAPI (blue), β-tubulin (red) and
Anti-Acheron (green) plotted relative to area on the cell. Anti-Acheron (green) fluorescence
intensity can be seen almost perfectly overlapping with β-tubulin (red) fluorescence while DAPI
fluorescence remains partially discrete.

In order to test the hypothesis that Acheron binds also to microtubules in differentiated
skeletal muscle, we induced myotube formation in cycling C2C12 myoblasts. Myotubes were
stained for Acheron (green), DNA (blue) and β-tubulin (red). Slides were then imaged at 60X on
a Nikon A1R-SIMe resonant scanning confocal super resolution microscope (Figure 4a). In this
Figure, myoblasts can be seen as mononucleated cells while each myotube is mutli-nucleated
indicating that each tube has fully differentiated. Here Acheron can be seen forming yellow
regions of the image with β-tubulin, indicating colocalization. Acheron fluorescence (and
therefore expression) is also notably increased from Figures 3a and 3c. This validates prior
observations that Acheron expression increases in differentiated C2C12 myotubes. This also
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supports our hypothesis that Acheron binds to microtubules in differentiated myotubes (Figure
4a). To further resolve these findings, we again analyzed the images graphically.
Similar to Figures 3b and 3d, in this graph, the DAPI signal is represented as the blue
line, while Acheron and β-tubulin are represented by green and red lines (respectively) (Figure
4b). In blue, the multiple nuclei of our mutli-nucleated myotube can be seen represented by
multiple blue peaks. Acheron (green) and β-tubulin (red) once again follow an almost exact
expression pattern (Figure 4b). This further supports our hypothesis that Acheron binds to
microtubules in differentiated C2C12 myotubes.

Figure 4a. Super Resolution Subcellular Localization of Acheron Relative to Microtubules
in C2C12 Myotubes.
A confocal z-stack of the nucleus (DAPI; blue; far left), microtubules (E7; red; second to
the left), Acheron (anti-Acheron; green; second to the right) and composite (merge; far right)
channels of a single stained cycling mononucleated C2C12 myoblast, imaged at 60X.
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Figure 4b. Colocalization analysis of DAPI, Acheron and β-tubulin Fluorescent Signal From
Figure 4a.
A graphical representation of fluorescence intensity for DAPI (blue), β-tubulin (red) and
Anti-Acheron (green) plotted relative to area on the cell. Acheron (green) fluorescence intensity
substantially overlaps with β-tubulin (red) fluorescence while multiple nuclei of the multinucleated myotube can be seen as discrete DAPI fluorescence peaks.

In order to test the hypothesis that Acheron binds to microtubules in non-muscle cells, we
turned to human U2-OS osteosarcoma cells. U2-OS cells are a bone cancer cell line derived from
the moderately differentiated sarcoma of the tibia of a 15-year-old girl (Rousseau, 2010). These
cells are commonly utilized in fluorescent microscopy due to their large size and flat shape
(Rousseau, 2010). These features allow for high resolution imaging and therefore high precision
colocalization analysis. Additionally, U2-OS cells endogenously express Acheron, making them
an valuable tool for extending our analyses (Human Protein Atlas). Samples were prepared for
immunofluorescence the same manner as for C2C12 myoblasts above and probed for Acheron
(green), DNA (blue) and β-tubulin (red). Slides were then imaged at 100X on a Nikon A1R-SIMe
resonant scanning confocal super resolution microscope (Figure 5a). For this Figure, the
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resolution provided to us by the scanning confocal super resolution microscope combined with
some fortunate timing, allowed us to not only test our hypothesis, but capture additional data by
imaging a cell undergoing mitosis. In Figure 5a, DAPI staining can be seen in the nucleus of the
cell as expected, however, multiple discrete foci of DAPI staining can be seen. In this image,
DAPI staining allows for visualization of condensed chromosomes that are attached to
kinetochore microtubules as they align to the metaphase plate. The microtubules (red) can be seen
exerting tension on the chromosomes. In cycling cells undergoing metaphase and anaphase,
microtubules of the cell dedicate themselves to the purpose of cell division (Oriola et al.,
2018). Acheron (green) can be seen largely colocalizing with the microtubules of the cell
(yellow) (Figure 5a). Taken together, the data from this image not only supports our hypothesis
that Acheron binds to microtubules in multiple mammalian lineages, but also informs us that
Acheron/microtubule binding is retained even during cell division steps where microtubules are
repurposed such as metaphase (Figure 5a).
Graphical analysis of the image provides us with the ability to visualize our
colocalization relative to distance across the cell (microns) and gauge relative expression levels of
our probed proteins and structures (Figure 5b). In this graph, DAPI staining is seen as the blue
line while Acheron and β-tubulin are represented by green and red lines, respectively. Similar to
Figures 3b, d and 4b, Acheron fluorescence can be seen almost identically matching the β-tubulin
fluorescence pattern, while DAPI signal can be seen discreetly. These data can be used to
demonstrate that our yellow colocalization signaling is not an artifact of two signals stacked but
represents genuine colocalization.
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Figure 5a. Acheron’s Microtubule Localization is Preserved Between Different Mammalian
Cell Lines.
A confocal z-stack of the nuclei (DAPI; blue; far left), microtubules (E7; red; second to
the left), Acheron (anti-Acheron; green; second to the right) and composite (merge; far right)
channels of a single stained cycling U2-OS osteosarcoma cell, imaged at 100X. A substantial
portion of Acheron in the cell can be seen colocalizing with microtubules in yellow regions of the
image, while DAPI signal can be used to see chromosomes aligning to the metaphase plate.

38

Figure 5b. Colocalization analysis of DAPI, Acheron and β-tubulin Fluorescent Signal From
Figure 5a.
A graphical representation of fluorescence intensity for DAPI(blue), β-tubulin (red) and
Anti-Acheron (green) plotted relative to area on the cell. Anti-Acheron (green) fluorescence
intensity can be seen following the same distal trajectory as β-tubulin (red), while DAPI (blue)
peaks can be seen in their own unique areas of the cell.

In order to better determine if Acheron physically binds to microtubules in mammalian
cells, we hypothesized that depolymerizing microtubules would liberate Acheron into the
cytoplasm. To test this hypothesis, we employed the antineoplastic agent Nocodazole to induce
microtubule depolymerization and disrupt microtubule associated protein (MAP) interactions
(Verstraelen et al., 2017). Cells were treated with Nocodazole and then probed for Acheron
localization to microtubules.
To determine the optimal concentration for Nocodazole treatment, I performed a
dose/response analysis to evaluate both microtubule depolymerization with immunofluorescence
and apoptosis (phase contrast imaging of membrane blebbing). The results of these studies
allowed us to determine the optimal conditions of Nocodazole treatment that successfully
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depolymerized microtubules but did not trigger cell death. In phase imaging, both membrane
blebbing and vesicle formation, can be seen in doses of 750 nM for 1 hour (Figure 6a). As a
result, any doses beyond this range we’re immediately excluded from microtubule analysis as
they would kill the cell. Cells treated with varying dilutions of Nocodazole below 750 nM for 1
hour were stained for microtubules (E7; magenta) and nuclei (DAPI; cyan) and imaged at 60X
(Figure 6b). Nocodazole treatment failed to depolymerize microtubules in C2C12 myoblasts until
400 nM for 1 hour. At this point microtubules appear to be completely depolymerized (Figure
6b). Taken together, the data from these studies indicates the ideal dilution and incubation time
for Nocodazole mediated microtubule depolymerization in cycling C2C12 myoblasts is between
400-750 nM for 1 hour.
C2C12 cells were then treated with 500 nM Nocodazole for 1 hour and fixed on poly-Llysine treated coverslips and probed for Acheron (green), DNA (blue) and β-tubulin (red). Slides
were then imaged at 100X on a Nikon A1R-SIMe resonant scanning confocal super resolution
microscope (Figure 6c). In this figure, microtubule fragments can be seen in red, indicating
complete depolymerization of the microtubule. However, Acheron (green) can still be seen
localizing to β-tubulin (red) in areas of yellow (Figure 6c). Accumulations of Acheron and βtubulin can be seen in perinuclear areas of the cell while an absence of membrane blebbing and
vesicle formation informs us that we did not trigger apoptosis of the cell with a 500nM treatment
of Nocodazole (Figure 6c).
In Figure 6d this data is represented graphically. Peaks of Acheron (green) and β-tubulin
(red) can be seen in areas around the DAPI (blue) signal indicating perinuclear accumulation.
Acheron expression can also be seen following a similar trajectory to β-tubulin, with less
expression of Acheron towards the edge of the cell (Figure 6d). These findings, combined with
our prior data, supports the hypothesis that Acheron not only binds to microtubules, but
individual β-tubulin monomers (Figure 6c, Figure 6d).
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Figure 6a. Phase Contrast Images of Nocodazole Treated C2C12 Myoblasts.
Phase z-projections of cycling mononucleated C2C12 myoblasts in response to varying
dosages of Nocodazole. Arrows indicate areas showing hallmarks for apoptosis such as vesicle
formation and membrane blebbing. Imaged at 60X.
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Figure 6b. Immunofluorescent Staining of Nocodazole Treated C2C12 Myoblasts.
Composite z-projections of nuclei (DAPI; cyan) and microtubules (E7; magenta) in
cycling mononucleated C2C12 myoblasts in response to varying dosages of Nocodazole. Imaged at
60X.
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Figure 6c. Acheron localizes to Individual β-tubulin Monomers in Nocodazole Treated
C2C12 Myoblasts
A confocal z-stack of the nucleus (DAPI; blue; far left), microtubules (E7; red; second to
the left), Acheron (anti-Acheron; green; second to the right) and composite (merge; far right)
channels of a single stained cycling mononucleated C2C12 myoblast treated with 500nM
Nocodazole for 1 hour, imaged at 100X. Here Acheron can still be seen colocalizing with
microtubules, however the majority of Acheron signal is peri-nuclear.
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Figure 6d. Colocalization analysis of DAPI, Acheron and β-tubulin Fluorescent Signal From
figure 6c.
A graphical representation of fluorescence intensity for DAPI (blue), β-tubulin (red) and
Anti-Acheron (green) plotted relative to area on the cell. Despite microtubule depolymerization,
Acheron can be found in identical areas as depolymerized tubulin monomers while DAPI signal
can be seen isolated to the nucleus.

BAD, HHARI and CASK Localization in C2C12 Myoblasts:
Acheron plays a crucial role in processes of PCD, myogenesis and pathogenesis. Prior
data from the lab suggests Acheron interacts with the BH3-only protein BAD; the E3 ubiquitin
ligase HHARI; and the Calcium/Calmodulin-dependent Serine Protein Kinase, CASK.
Consequently, understanding the subcellular localization of these molecules in reference to
Acheron, and determining if these molecules are directly complexed with Acheron, would
provide us with critical information regarding Acheron’s role in these cellular processes. To test
the hypothesis that Acheron co-localizes with known binding partners (BAD, HHARI and
CASK) at the microtubules of the cell, C2C12 myoblasts were plated on poly-L-lysine coverslips
and immunostained for BAD, HHARI and CASK in relation to microtubules. As described above
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for the other images, areas of colocalization between BAD, HHARI, CASK (green) and β-tubulin
(red) can be inferred from orange/yellow signals.
Co-IP of Acheron in C2C12 myoblasts demonstrated a physical interaction with the BH3only protein BAD (Sheel et al., 2020). Given our prior findings that Acheron binds to
microtubules and BAD could be found binding to Acheron, I sought to determine if BAD could
also be found localizing to microtubules in C2C12 myoblasts. Myoblasts were stained for DNA
(blue), BAD (green) and β-tubulin (red). Slides were then imaged at 100X on a Nikon A1R-SIMe
resonant scanning confocal super resolution microscope (Figure 7a). The resulting composite
image appears to be devoid of yellow areas, indicating a lack of observable colocalization. BAD
(green) can be seen following a punctate pattern in the cytosol rather than a filamentous pattern
that is characteristic of Acheron (Figures 3a; 3c; 4a; and 5a).
When plotted graphically, the fluorescence intensities of each color channel support our
findings that BAD does not bind to microtubules in C2C12 myoblasts (Figure 7b). Here BAD
(green) signal can be seen following a fluorescence pattern independent of β-tubulin (red) and
DAPI (blue). Peaks of BAD expression can be seen in perinuclear areas of the cell, similar to our
prior expression of mitotracker (Figures 1a-c). As a whole, these datas do not support the
hypothesis that BAD localizes to microtubules in C2C12 myoblasts.
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7a. Super Resolution Subcellular Localization of BAD Relative to Microtubules in C2C12
Myoblasts.
A confocal z-stack of the nuclei (DAPI; blue; far left), microtubules (β-tubulin; red;
second to the left), BAD (anti-BAD; green; second to the right) and composite (merge; far right)
channels of a single stained cycling C2C12 myoblast, imaged at 100X.

Figure 7b. Colocalization analysis of DAPI, BAD and β-tubulin Fluorescent Signal From
Figure 7a.
A graphical representation of fluorescence intensity for DAPI (blue), β-tubulin (red) and
Anti-BAD (green) plotted relative to area on the cell. Anti-BAD (green) fluorescence intensity
can be seen following a separate distal trajectory from β-tubulin (red), while slightly overlapping
with DAPI signal.
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Co-IP and Yeast 2-Hybrid screening revealed binding of the ubiquitin ligase, Human
Homolog of Ariadne-1 (HHARI) to Acheron, (Wang Z, 2003). This data, combined with the fact
that Acheron binds to microtubules in mammalian cells, motivated me to test the hypothesis that
HHARI might also be found to be associated with microtubules in mammalian cells.
C2C12 cells were stained for DNA (blue), HHARI (green) and β-tubulin (red). Slides were
then imaged at 100X on a Nikon A1R-SIMe resonant scanning confocal super resolution
microscope (Figure 8a). Similar to Figure 7a, there is no observable region of yellow staining,
suggesting the absence of colocalization. Instead, HHARI can be observed to aggregate at
specific perinuclear areas of the cell. While this area is not colocalizing with microtubules and is
therefore not at the centrosome of the cell, it can instead be inferred that HHARI is localizing to
the golgi apparatus, with some additional signal in the nucleoplasm (Figure 8a).
This is seen graphically in Figure 8b. In this Figure HHARI fluorescent signal can be
seen in green, while β-tubulin and DAPI signal can be seen in red and blue, respectively. Here
HHARI appears to be completely independent of β-tubulin expression, aggregating at one end of
the nucleus with some additional HHARI expression inside the nucleus of the cell (Figure 8b).
These findings do not support the hypothesis that HHARI binds to microtubules in C2C12
myoblasts.
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8a. Super Resolution Subcellular Localization of HHARI Relative to Microtubules in C2C12
Myoblasts
A confocal z-stack of the nuclei (DAPI; blue; far left), microtubules (β-tubulin; red;
second to the left), HHARI (anti-HHARI; green; second to the right) and composite (merge; far
right) channels of a single stained cycling C2C12 myoblast, imaged at 100X.

Figure 8b. Colocalization analysis of DAPI, HHARI and β-tubulin Fluorescent Signal From
Figure 8a.
A graphical representation of fluorescence intensity for DAPI (blue), β-tubulin (red) and
Anti-HHARI (green) plotted relative to area on the cell. Here HHARI fluorescence can be seen in
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large amounts around the edge of the nucleus with less inside the nucleus. Signals here do not
coincide with β-tubulin fluorescence.

Yeast 2-hybrid screening of Acheron and mouse embryonic cDNA revealed CASK binds
to the C-terminus of Acheron via CASK’s CaM K II like domain (Wang et al., Unpublished).
CASK’s localization to the cytoplasm and nucleus of the cell has been well documented.
However, our data that CASK binds to Acheron, a microtubule localized protein, led us to
hypothesize that a portion of CASK may localize to areas of known Acheron localization in
mammalian cells.
To test the hypothesis that CASK localizes to microtubules of C2C12 cells, C2C12
myoblasts were stained for DNA (blue), CASK (green) and β-tubulin (red). Slides were then
imaged at 100X on a Nikon A1R-SIMe resonant scanning confocal super resolution microscope
(Figure 9a). Just as Figure 7a and 8a, this image is completely absent of yellow coloring,
indicating the absence of colocalization. In this Figure, CASK localizes to the cytoplasm and
nucleus, in agreement with published reports (Human Protein Atlas) (Figure 9a). This is made
especially apparent in figure 9b. Graphically, CASK (green)), βtubulin (red) and DAPI (blue)
signal appear to occupy independent locations within the cell with the exemption of a small spike
in CASK signal overlapping with DAPI, suggesting that some CASK localizes to the nucleus
(Figure 9b). Taken together this data supports the hypothesis that CASK localizes to the nucleus,
an area commonly associated with Acheron localization.
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9a. Super Resolution Subcellular Localization of CASK Relative to Microtubules in C2C12
Myoblasts
A confocal z-stack of the nuclei (DAPI; blue; far left), microtubules (E7; red; second to
the left), CASK (anti-CASK; green; second to the right) and composite (merge; far right)
channels of cycling C2C12 Myoblasts, imaged at 100X.

Figure 9b. Colocalization analysis of DAPI, CASK and β-tubulin Fluorescent Signal From
Figure 9a.
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A graphical representation of fluorescence intensity for DAPI (blue), β-tubulin (red) and
anti-CASK (green) plotted relative to area on the cell. In this Figure, anti-CASK (green)
fluorescence intensity can be seen following a separate distal trajectory from β-tubulin (red).
However, some anti-CASK expression can be seen aggregating in the nucleus near the DAPI
signal.
Acheron is a dynamic protein with functional nuclear localization (NLS) and nuclear
export signals (NES) (Valavanis et al., 2009; Shao et al., 2012). Initial studies reveal that Acheron
localizes to not only microtubules, but also to the nucleus (Fig. 1c). Translocation of Acheron into
and out of the nucleus can be triggered in response to increasing and decreasing growth factors,
respectively (Glenn et al., unpublished). While the cytoplasmic localization of CASK has been
well documented in the cytoplasm and nucleus of the cell (Gardener et al., 2006), CASK lacks a
nuclear localization signal, so the mechanism that facilitates translocation is unclear. Prior studies
suggest that ectopic expression of CASK and a cytoskeletal localized T-box transcription factor,
T-brain-1 (Tbr-1) results in nuclear translocation of CASK (Bredt et al., 2000). These findings
combined with our knowledge that Acheron binds to CASK and localizes to microtubules led us
to question if Acheron acted as a shuttle protein for CASK into the nucleus.
To test the hypothesis that CASK translocates to the nucleus when Acheron translocation
is induced, we utilized two different lines of C2C12 cells expressing ectopic Acheron (Shao et al.,
2012). The first line was transfected with a plasmid coding for the expression of full-length HAtagged Acheron, driven by a pCMV-Neo retroviral promoter. The second line was transfected
with a mutated version of Acheron that lacks the nuclear export signal (Shao et al., 2012). This in
turn causes nuclear Acheron to become trapped in the nucleus and allows us to image the cells in
a time-independent fashion.
Both lines were plated on poly-L-lysine coated coverslips and grown in standard C2C12
growth medium. When cells reached 70% confluency, Acheron was chased into the nucleus by
increasing concentrations of growth factors as described above and cells were fixed. Cells were
then stained for Acheron (green), β-tubulin (red) and DAPI (blue) and imaged at 100X (Figure
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10a). For this experiment control images of both cell lines (C2C12 + HA + Acheron and C2C12 +
HA + Acheron -NES) stained for Acheron (green), β-tubulin (red) and DAPI (blue) can be seen in
supplemental Figures 2a and 3a. In these images Acheron can be seen localized to microtubules
of the cell. Acheron does not begin to aggregate around the nucleus until serum is increased in NES cells.
Within Figure 10a, cells in standard 10% FBS can be seen in the top half of the Figure,
while cells cultured in 15% FBS with nonfunctional NES can be seen in the bottom half. Acheron
(green) can be seen localized to microtubules (red), in agreement with our prior images. This is
demonstrated by the strong yellow coloring seen in the composite image on the right (Figure
10a). However, when -NES cells were incubated in 15% FBS, Acheron (green) became trapped
in the nucleus (blue) with lower levels of expression associated with microtubules (red) (Figure
10a).
This is seen in even greater detail in Figures 10b and 10c. In Figure 10b, fluorescent intensities of
the 10% FBS sample can be seen graphically. Here, Acheron fluorescent intensity (green) can be
seen following β-tubulin (red) expression. Low levels of Acheron can be seen near the DAPI
(blue) signal indicating low levels of Acheron staining in the nucleus (Figure 10b).
In contrast Figure 10c shows fluorescent intensities of the 15% -NES sample. In this
image Acheron (green) expression can be seen following β-tubulin (red) fluorescent intensity, but
to a lesser extent. Instead, large peaks of Acheron (green) signal can be seen aggregating with
DAPI (blue) signal at the nucleus of the cell. Taken together, this data confirms that Acheron can
be driven into the nucleus of the cell in response to increasing concentrations of growth factors.
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Figure 10a. Acheron Nuclear Translocation in Response to Increased Growth Factors in
C2C12 Myoblasts.
A confocal z-stack of the nuclei (DAPI; blue; far left), microtubules (E7; red; second to
the left), Acheron (anti-Acheron; green; second to the right) and composite (merge; far right)
channels of a single stained modified C2C12 cell, imaged at 100X.
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Figure 10b. Colocalization analysis of DAPI, Acheron and β-tubulin Fluorescent Signal in
C2C12 Myoblasts in 10% FBS.
A graphical representation of fluorescence intensity for DAPI (blue), β-tubulin (red) and
anti-Acheron (green) in 10% FBS samples, plotted relative to area on the cell. In this Figure, antiAcheron (green) fluorescence intensity can be seen matching expression localization for β-tubulin
(red) signal. However, low levels of Achron (green) can be seen in the nucleus near the DAPI
(blue) signal.
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Figure 10c. Colocalization analysis of DAPI, Acheron and β-tubulin Fluorescent Signal in
C2C12 Myoblasts in 15% FBS.
A graphical representation of fluorescence intensity for DAPI (blue), β-tubulin (red) and
anti-Acheron (green) in 15% FBS samples, plotted relative to area on the cell. In this figure, antiAcheron (green) fluorescence intensity can be seen matching expression localization for β-tubulin
(red) signal, however, in stark contrast to Figure 10b, Acheron (green) can be seen aggregating in
the nucleus of the cell near DAPI (blue) signal.
To further test the hypothesis that CASK translocates to the nucleus of mammalian cells
when Acheron translocation is induced, the experiment was repeated except that slides were
probed for CASK (green), β-tubulin (red) and DNA (blue) (Figure 11a).
The resulting panel of images is formatted in the same manner as Figure 10a. In this
figure, cells that were not exposed to increased levels of growth factors can be seen in the top half
of the figure, while-NES cells incubated in elevated serum are shown on the bottom half.
In the 10% FBS cells, CASK (green) can be seen localized to the cytoplasm of the cell, separate
from microtubules (red). This agrees with data from Figure 9a. In the 15% FBS -NES cells,
CASK (green) is seen behaving differently. Unlike before, there is a dramatic increase in CASK
(green) expression in these cell lines, with green signal much more prevalent than its 10% FBS
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counterpart. Much of the signal can also be seen in the nucleus (blue) with some signal localizing
to microtubules (red), as denoted by the yellow coloring (Figure 11a). CASK localization in both
samples is better visualized graphically in Figures 11b and 11c.
In Figure 11b, CASK fluorescent intensities (green) can be seen to accumulate around the
DAPI (blue) signal, in the perinuclear space. As well as this, CASK (green) signal can be seen
following a fluorescent intensity pattern independent of β-tubulin (red) signal (Figure 11b).
In Figure 11c, CASK fluorescent signal (green) can be seen accumulating in the nucleus,
in proximity to DAPI (blue) signal, to a greater extent than in Figure 11b. Comparatively, this
indicates successful translocation of CASK (green) to the nucleus of the cell in response to
increasing growth factors. However, in stark contrast to our prior CASK data, in 15% FBS
samples CASK (green) fluorescent signal can be seen closely following the β-tubulin (red) signal,
indicating localization to microtubules (Figure 11c).

Figure 11a. CASK Nuclear Translocation in Response to Increased Growth Factors in
C2C12 Myoblasts.
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A confocal z-stack of the nuclei (DAPI; blue; far left), microtubules (E7; red; second to
the left), CASK (anti-CASK; green; second to the right) and composite (merge; far right)
channels of a single stained modified C2C12 cell, imaged at 100X.

Figure 11b. Colocalization analysis of DAPI, CASK and β-tubulin Fluorescent Signal in
C2C12 Myoblasts in 10% FBS.
A graphical representation of fluorescence intensity for DAPI (blue), β-tubulin (red) and
Anti-CASK (green) in 10% FBS samples, plotted relative to area on the cell. In this Figure, antiCASK (green) fluorescence intensity can be seen following an fluorescent signal intensity path of
β-tubulin (red), aggregating in the perinuclear space in proximity to DAPI (blue) signal.
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Figure 11c. Colocalization analysis of DAPI, CASK and β-tubulin Fluorescent Signal in
C2C12 Myoblasts in 15% FBS.
A graphical representation of fluorescence intensity for DAPI (blue), β-tubulin (red) and
Anti-CASK (green) in 15% FBS samples, plotted relative to area on the cell. In this Figure, antiCASK (green) fluorescence intensity can be seen localizing to DAPI (blue) signal in greater
quantities than in its 10% FBS counterpart. In stark contrast to Figure 11b, here CASK (green)
fluorescence signal intensity can be seen closely following β-tubulin (red) expression as well.

58

Discussion:
The purpose of the experiments described above was to conduct two studies. In the first
study I set out to determine the subcellular localization of Acheron. In line with this goal, I tested
the hypotheses that Acheron: localizes to mitochondria; binds to actin; and binds to microtubules
in mammalian cells. I utilized undifferentiated C2C12 myoblasts, differentiated C2C12 myotubes,
and U2-OS osteosarcoma cells. I then tested the hypothesis that Acheron localization was
occurring directly via Acheron-β-tubulin interactions.
In the second study, I tested the hypothesis that Acheron colocalizes with specific binding
partners: BAD, Human Homology of Ariadne-1 (HHARI) and Calcium/Calmodulin-dependent
Serine Protein Kinase (CASK). I further tested the hypothesis that Acheron can facilitate the
translocation of CASK into the nucleus of mammalian cells.
Overall, the results of these studies suggest that Acheron binds to microtubules in a
variety of cell types and that this localization is mediated directly through Acheron-β-tubulin
binding. However, the results of these studies did not support the hypothesis that Acheron and
BAD and Acheron and HHARI can be found colocalizing at the microtubules of the cell together.
The data from this study did support the hypothesis that Acheron can facilitate the translocation
of CASK into the nucleus of mammalian cells.
The data of the first study can be seen in Figures 1-6. In Figure 1a, Acheron could be
seen predominantly within the nucleus and following a reticulated pattern in the cytoplasm. The
cytoplasmic signal however, followed a specific reticulated pattern (Figure 1a). Graphically,
while there is some coincidence of Acheron and Mitotracker signal around the nucleus (45um and
90um), the Acheron signal could be seen occupying space that is primarily independent of the
Mitotracker fluorescence. Acheron fluorescence did appear to overlap with the DAPI signal in the
nucleus, however not with the peaks of DAPI (blue) signal seen around 55um and 75um. These
peaks can be seen on Figure 1a as the brighter blue spots within the nucleus of the cell that may
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represent tightly condensed heterochromatin (Linhoff et al., 2015). The separation of Acheron
fluorescence and heterochromatin supports the hypotheses that while Acheron can be found in the
nucleus, it does not bind directly to the DNA, although this awaits direct testing. A closer
examination reveals that the Acheron signal presented in Figure 1 in the cytoplasm is not diffuse,
but instead follows a specific cytoskeletal pattern. This led us to hypothesize that Acheron binds
to a cytoskeletal structure such as actin or tubulin. In contrast to its cytoplasmic staining, nuclear
Acheron appears to be diffuse rather than following a specific identifiable pattern. Interestingly,
perinuclear Acheron appears to follow its own unique pattern that is independent of both
cytoskeletal and nuclear signals. With the enhanced resolution provided by Figure 1c, Acheron
can be seen surrounding the nuclear envelope while a separate almost horizontal pattern can be
seen protruding out of the nucleus into the cytoplasm. This leads us to hypothesize here that
Acheron may be localizing to ribosomes and the rough endoplasmic reticulum of the cell,
respectively.
Similar to the data presented by Dermit et al, (2020) aggregates of Acheron could be seen
at the periphery of the cell (Figure 1b). These areas of elevated Acheron signal do not localize to
the leading edge of the cell, as would be expected for lamellipodia. Instead, these areas of
elevated Acheron signal localize to protrusions extending out of the cell, consistent with
filopodia. This supports the recent data presented by Dermit et al., (2020) demonstrating that
Acheron is enriched at actin-rich cell protrusions. Taken together, the data from Figures 1a, 1b
and 1c support the hypothesis that Acheron binds to a cytoskeletal structure in the cytoplasm. In
addition, the data acquired in this study provides us with enhanced resolution and information
regarding not only the perinuclear localization of Acheron but also the enriched areas of Acheron
at the filopodia of the cell.
However, analysis of Acheron staining in this cell reveals many of the same observations
from Figures 1a, b and c. Acheron has a pattern in the nucleus with increased expression in the
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perinuclear space. A closer analysis reveals that Acheron expression has a reticulated pattern in
the cytoplasm (Figures 1a and 1c). Brighter areas of enriched Acheron signal can be seen at the
ends of actin filaments as before. This supports both the hypothesis that: a) areas of Acheron
staining are not artifactual, but rather a reproducible phenomenon that supports the data presented
by Dermit et al (2020); and b) these enriched areas can be found at the filopodia of the cell and
not just at cellular protrusions. However, filopodia are actin rich structures and the data presented
above demonstrate that Acheron does not localize to actin filaments (Figures 2a and 2b). In order
to address this conundrum, we probed cells for microtubules, a distinct cytoskeletal structure
associated with filopodia. In Figure 3a and 3c we probed cycling C2C12 myoblasts for Acheron,
DNA and microtubules. Unlike Figures 1 and 2, in these images the cytoplasmic Acheron and
microtubule fluorescence signals are colocalized, within the limit of resolution. This is indicated
by yellow fluorescence (Figures 3a, 3c). This supports the hypothesis that Acheron localizes to
microtubules in mammalian cell lines.
In order to test the hypothesis that Acheron-microtubule localization is retained with
during development, we differentiated C2C12 myoblasts into myotubes and stained them for
Acheron, DNA and microtubule filaments (Figure 4a). In the resulting figure, we found that
Acheron expression was dramatically increased and that the signal was predominantly
cytoplasmic and associated with the cytoskeleton rather than predominant nuclear staining seen in
cycling cells. This is seen visually in Figure 4a as well as graphically in Figure 4b. Dips of
Acheron expression when DAPI expression peaks informs of Acheron's affinity towards the
cytoplasm rather than the nucleus in differentiated myotubes (Figure 4b). This suggests that
Acheron localization is developmentally-regulated in mouse myoblasts and myotubes. This leads
us to speculate that Acheron plays roles in the nucleus and cytoplasm of cycling cells but is
restricted to the cytoplasm following differentiation. (Figure 4a).
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To extend our analyses, we wanted to determine if Acheron binding to microtubules is
restricted to C2C12 cells or a more general phenomenon, we immunostained cycling U2OS human
osteosarcoma cells for Acheron, DNA, and microtubules (Figure 5a). We confirmed that
Acheron binds to microtubules in U2OS cells. This is demonstrated by the yellow fluorescence
in the composite channel as well as by the overlap in the graphed Acheron (green) and β-tubulin
(red) fluorescence intensities (Figure 5a and 5b). In agreement with the data from C2C12 cells, we
also see nuclear Acheron staining (green) that appears to be excluded from the DNA DAPI (blue)
signal (Figure 5b). For this figure we were fortunate enough to capture a cell at the metaphase of
mitosis. The condensed chromosomes can be seen attached to kinetochore microtubules as they
align to the metaphase plate. Acheron co-localizes with the microtubules but not with the
chromosomes (Figure 5a and 5b). Taken together, this data supports the hypothesis that Acheron
binds to microtubules and that this Acheron-microtubule binding is conserved within
mammalians. It also supports the hypothesis that nuclear Acheron does not bind directly to DNA.
Finally, in order to test the hypothesis that Acheron-microtubule localization is conserved
when subject to microtubule depolymerization, cycling C2C12 myoblasts were treated with
Nocodazole and probed for Acheron, DNA, and microtubules (Figure 6c). Here the optimal dose
of Nocodazole was empirically determined to be 500nM for 1 hour. This dosage was found to
fully depolymerize microtubules but does not immediately induce apoptosis (Figures 6a and 6b).
Surprisingly, even with depolarization, Acheron was found to retain microtubule binding, as
indicated by yellow fluorescence in the composite channel. Acheron signal is clearly diffuse
however yellow fluorescence and signal overlap can be seen, indicating colocalization with βtubulin monomers (Figure 6c and 6d). This provides us with new insights into Acheron’s
microtubule localization. When considered with the data above, the results of this assay support
the hypothesis that Acheron localizes to microtubules in mammalian cells, and that this
localization is specific to the individual microtubule monomer, β-tubulin (Figure 6c and 6d).
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This conclusion is further supported by Acheron’s La motif. Acheron’s structure
contains; a functional nuclear localization signal (NLS), a nuclear export signal (NES), a Suz-C
(subcellular localization and mRNA substrate recognition) domain, a well-conserved RNA
recognition motif (RRM) and a functional, winged helix-turn-helix structured RNA binding, LA
motif (LAM) (Stefanovic et al., 2014; Martino et al., 2015; Bousquet-Antonelli et al., 2009; Dong
et al., 2004; Valavanis et al., 2007; Stavraka et al., 2015). X-Ray Crystallography and
Crosslinking/Mass Spectrometry (MS) data reveals individual alpha and beta tubulin monomers
interact with winged-helix protein domains via it’s Carboxy-terminus (Abad et al., 2014).
Acheron staining in various experimental conditions not only reveals new information
regarding Acheron-microtubule localization, but also other facets of Acheron localization such as
it’s nuclear, perinuclear and filopodia localization. The increased yellow fluorescence around the
nucleus reveals new information about Acheron’s perinuclear expression. While this spike in
Acheron expression could mean Acheron localizes to the cell’s rough endoplasmic reticulum or
Golgi Apparatus, the presence of yellow colocalization with microtubules informs us that this
localization is likely to the centrosome, one of the main microtubules organizing centers of the
cell. Filopodia are actin rich structures (Mattila and Lappalainen, 2008). We have found that
Acheron does not associate with phalloidin-stained structures within the cell (Figure 2) yet it is
enriched, at the filopodia (Figure 2b). This phenomenon is best explained by microtubule
involvement in cell proliferation. During cell proliferation and migration, microtubules and actin
filaments work against each other to regulate cell movement within structures known as growth
cones (Khan and Baas, 2016). Filopodia are dominant structures within growth cones (Davenport
et al., 1993). As a result, Acheron could be localized to microtubules within these structures.
Recent data also supports the hypothesis that microtubules may directly participate in directed
cell motility via filopodia merging and control of filopodia density (Schober et al., 2007).
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Therefore, one proposed interpretation is that Acheron may also be localized and enriched at the
microtubules involved in controlling filopodia dynamics.
In almost all experimental conditions, relative levels of Acheron signal can be seen in the
nucleus. However, in no circumstances do graphed expression intensities of nuclear Acheron
(green) coincide with peaks of brighter DAPI expression (blue). Given previous studies that have
demonstrated pericentric heterochromatin is easily detectable as large DAPI-dense foci, the data
presented in this study suggests that while Acheron localizes to the nucleus, it does not bind
directly to DNA and therefore does not become enriched at bundles of heterochromatin or
condensed chromosomes (Imai et al., 2017). This provides new insight into the mechanism
guiding Acheron’s function as an RNA binding protein.
The nucleoli of the cell are home to a plethora of mRNA molecules. Subsequently, many
RNA binding proteins can be found localized to nucleoli as well (Nazer et al., 2011). However,
recent data has shown the importance of heterochromatin localization to the periphery of nucleoli
of the cell. Enhanced resolution provided by super resolution microscopy suggests that Acheron
does not localize to DNA and therefore heterochromatin itself and Acheron is not found in
nucleoli/on the periphery of nucleoli (Guetg and Santoro, 2012). This data, combined with
Acheron’s demonstrated role in ribosome biogenesis (Dermit et al., 2020) , a process that begins
in the nucleolus and finishes in the cytoplasm of eukaryotic cells, leads us to infer that Acheron’s
role in ribosome biogenesis is independent of nucleoli localization and must occur in cytoplasm
(Pelletier et al., 2018).
Ribosome biogenesis originates in the nucleolus transcription and assembly of preribosomes (pre-40s, pre-60s) occur. Synthesized pre-ribosomes then travel through the
nucleoplasm and into the cytoplasm where they mature into ribosomal 40S and 60S subunits that
comprise the ribosome (Thomson et al., 2013). Taken together, the data of these studies suggest
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that Acheron utilizes ribosomal subunits to play a role in regulating ribosome biogenesis.
However future studies are required to investigate this.
In summary, the experiments from this study demonstrate that Acheron localizes to
microtubules in mammalian cells, specifically to individual β-tubulin monomers and is enriched
in the growth cones of the filopodia. Finally, the data suggests that nuclear Acheron does not bind
directly to DNA, however future studies are required to investigate this.
Co-IP of Acheron in C2C12 myoblasts demonstrated a physical interaction with the BH3only protein BAD (Sheel et al., 2020). Given our prior findings that Acheron binds to both
microtubules and BAD, I sought to determine if BAD could also be found localizing to
microtubules in C2C12 myoblasts. The results of this study suggest BAD does not localize to
microtubules (Figure 7). Co-IP of Acheron in C2C12 myoblasts demonstrated a physical
interaction between Acheron and the BH3-only protein BAD, however super resolution
microscopy does not support the hypothesis that Acheron and BAD colocalize at the microtubules
of the cell together. One potential explanation revolves around post-translational modifications of
BAD.
The structure of BAD includes five serines that can be phosphorylated by different
kinases (Burlacu et al., 2003). These sites include Ser112, Ser128, Ser136, Ser155 and Ser179.
Immunofluorescent analysis reveals that BAD Ser128 can be found localized to the mitochondria
(Yang et al., 2008). However, phosphorylation of BAD at Ser155 induces translocation of BAD
to the cytoplasm and disruption of BAD binding to Bcl-2 (Datta et al., 2000). Future experiments
pursuing BAD / Acheron co-localization should monitor the localization of BAD in various
phosphorylated states. Phosphorylation often results in conformational changes and subsequent
exposed residues for potentially different binding partners (Groban et al., 2006). By monitoring
the localization of BAD in various phosphorylated states we can extend our co-IP data.
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Co-IP and Yeast 2-Hybrid screening revealed that Acheron binds to the ubiquitin E3
ligase, Human Homolog of Ariadne-1 (HHARI). In order to test the hypothesis that HHARI can
be found localized to microtubules in mammalian cells, cycling C2C12 myoblasts were
immunostained for HHARI, tubulin and DNA (Figure 8). We found that HHARI did not localize
to the microtubules. This data does not support prior Co-IP and Yeast 2-Hybrid findings that
HHARI binds to Acheron - a microtubule binding protein. One possible explanation for this
discrepancy could be found in Acheron and HHARI’s peri-nuclear signal.
We observed that HHARI does not localize to microtubules. However, Acheron and
HHARI can both be found in abundance around the nucleus (Figures 3b & 8b). Microtubule
organization is heavily reliant on microtubule-organizing centers (MTOCs) such as the
centrosome. These sites are responsible for microtubule organization, nucleation, and attachment
of microtubule minus ends (Conduit et al., 2015). Recent data reveals that the Golgi apparatus is
another site capable of nucleating and stabilizing microtubules (Chabin-Brion et al., 2001).
Resulting Golgi-derived microtubules are polarized and can therefore promote cell asymmetry
and polarized transport of post-Golgi carriers vital for cell migration (Vinogradova et al., 2012).
HHARI’s lack of microtubule localization suggests that this increase in perinuclear fluorescence
would not indicate centrosomal localization as with Acheron, but instead it can be inferred that
HHARI is localizing to the Golgi apparatus (Figure 8).
One hypothesis explaining the HHARI/Acheron binding demonstrated via co-IP and
Yeast-2-Hybrid can be found within the new data presented in this thesis. Acheron can be found
enriched at the filopodia of the cell, presumably within growth cones of proliferating cells
(Dermit et al., 2020) (Figures 1-6). In proliferating cells, polarized invasion of microtubules into
one side of the peripheral domain of the growth cone is required for dynamic growth cone
rotation (Kahn et al., 2016). As the Golgi apparatus serves as a MTOC of polarized microtubules,
HHARI’s localization to the Golgi may be linked with Acheron’s enrichment within growth
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cones of proliferating cells. Further studies should be performed to analyze Acheron enrichment
at the filopodia in HHARI deficient cells.
Yeast 2-hybrid screening of Acheron and mouse embryonic cDNA revealed CASK binds
to the C-terminus of Acheron via CASK’s CaM K II like domain (Wang et al., unpublished).
CASK localization to the cytoplasm and nucleus of the cell is already well documented (Ojeh et
al., 2008). Prior data demonstrates Acheron localizes to the microtubules and nucleus of the cell.
In order to test the hypothesis that CASK localizes to the microtubules of mammalian cells, I
stained cycling C2C12 myoblasts for CASK (green), β-tubulin (red) and DAPI (blue). The data
presented in this experiment suggests that CASK does not localize to microtubules in mammalian
cells.
Colocalization analysis reveals Acheron and CASK but do bind in yeast-2-hybrid assays.
. One plausible hypothesis for this discrepancy in data revolves around Acheron’s ability to
translocate in and out of the nucleus of the cell.
Acheron is a dynamic protein with a functional nuclear localization signal (NLS) and
nuclear export signal (NES) (Shao et al., 2012). As well, prior data from the lab has shown that
translocation of Acheron into and out of the nucleus can be triggered in response to increasing
and decreasing growth factors, respectively (Glenn et al., unpublished). CASK, while found
canonically in the nucleus and cytoplasm of the cell, lacks a nuclear localization signal (NLS)
(Gardener et al., 2006). As a result, the mechanism that facilitates its translocation is unclear. One
possible explanation could be that CASK-Acheron binding is a transient event that occurs when
Acheron shuttles CASK into the nucleus.
In Figures 10 and 11, I tested the hypothesis that CASK translocation to the nucleus is
correlated with Acheron translocation to nucleus, in response to increasing growth factors. Taken
together the data from this study suggests that CASK translocation to the nucleus is correlated
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with Acheron translocation to the nucleus, in response to increasing growth factors. Additionally,
the data presented in Figure 11a supports the hypothesis that CASK colocalizes with Acheron at
the microtubules of the cell during its translocation (Sonnen at al., 2012) (Figures 1-6).
In summary, our data supports the hypothesis that Acheron localizes to microtubules,
specifically to individual β-tubulin monomers, and is enriched in the growth cones of the
filopodia. Nuclear Acheron does not bind directly to DNA (future studies are required). Acheron,
BAD and HHARI do not colocalize with each other on microtubules of cycling mammalian
cells. CASK translocation to the nucleus is correlated with Acheron translocation to the nucleus
in response to increasing growth factors, and finally CASK colocalizes with Acheron at the

microtubules of the cell during its translocation.
These findings, while significant, raise the need for additional studies to not only analyze
the mechanisms guiding Acheron, HHARI, BAD and CASK localization in mammalian cells, but
to also corroborate the data presented above. Appropriate biochemical assays, including
fractionation and Western blotting, co-IPs, FRET, and should all be performed to confirm the
visual data presented by fluorescence microscopy above. These future experiments include, but
are not limited to; monitoring the localization of BAD and Acheron in various phosphorylated
states in mammalian cell lines, analysis of Acheron enrichment at the filopodia of HHARI
deficient and wild-type mammalian cells, and fractionated Western blotting of Acheron and
CASK in various cellular compartments in response to increasing growth factors.
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Supplemental Figures:

Supplemental Figure 1a. Super Resolution Subcellular Localization of Acheron Relative to
Microtubules in C2C12 Myoblasts Without -NES Deletion.
A graphical representation of fluorescence intensity for DAPI (blue), β-tubulin (red) and AntiAcheron (green) in 15% FBS samples, plotted relative to area on the cell.

69

Supplemental Figure 2a. Super Resolution Subcellular Localization of Acheron Relative to
Microtubules in -NES C2C12 Myoblasts.
A graphical representation of fluorescence intensity for DAPI (blue), β-tubulin (red) and AntiAcheron (green) in 15% FBS samples, plotted relative to area on the cell. In this Figure, anti-CASK (green)
fluorescence intensity can be seen localizing to DAPI (blue) signal in greater quantities than in its 10% FBS
counterpart. In stark contrast to Figure 11b, here CASK (green) fluorescence signal intensity can be seen
closely following β-tubulin (red) expression as well.
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Staining
405: DAPI
594: E7 Tubulin
650: Acheron

Cell Line
C2C12 Myoblast

File Name
100X WT C2C12
Ach E7 DAPI.nd2

405: DAPI
594: E7 Tubulin
650: Acheron

C2C12 Myotube

60X C2C12
Myotube Acheron
E7 DAPI.nd2

405: DAPI
594: E7 Tubulin
650: BAD

C2C12 Myoblast

100X WT C2C12
BAD E7 DAPI.nd2

405: DAPI
594: E7 Tubulin
650: HHARI

C2C12 Myoblast

100X WT C2C12
Ari E7 DAPI.nd2

405: DAPI
594: E7 Tubulin
650: CASK

C2C12 Myoblast

100X WT C2C12
CASK E7
DAPI.nd2

405: DAPI
594: E7 Tubulin
650: Acheron

C2C12 Myoblast +
Nocodazole

100X Nocodazole
C2C12 Ach E7
DAPI.nd2
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Single Slice Image

405: DAPI
594: E7 Tubulin
650: Acheron

C2C12 Myoblast

100X C2C12
+GFP Achn 10%
FBS Ach E7
DAPI.nd2

405: DAPI
594: E7 Tubulin
650: CASK

C2C12 Myoblast

100X C2C12
+GFP Achn 10%
FBS CASK E7
DAPI.nd2

405: DAPI
594: E7 Tubulin
650: Acheron

C2C12 +GFP Achn -

100X C2C12
+GFP Achn – NES
15% FBS Ach E7
DAPI.nd2

405: DAPI
594: E7 Tubulin
650: CASK

C2C12 Myoblast

NES 15% FBS

100X C2C12
+GFP Achn – NES
15% FBS CASK
E7 DAPI.tif

Table 2a. Appendix of Key Figures and Single Slice Representations:
A supplemental table documenting: file names, cell lines utilized, staining color
combinations and single slice representative images of key figures utilized in this dissertation.
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